UNITED STATES 

SECURITIES AND EXCHANGE COMMISSION 

Washington, D.C. 20549

 

FORM N-CSR

 

CERTIFIED SHAREHOLDER REPORT OF REGISTERED 

MANAGEMENT INVESTMENT COMPANIES

 

Investment Company Act file number: 811-21583

 

Clough Global Dividend and Income Fund

(exact name of registrant as specified in charter)

 

1290 Broadway, Suite 1000, Denver, Colorado 80203

(Address of principal executive offices) (Zip code)

 

Sareena Khwaja-Dixon, Secretary 

Clough Global Dividend and Income Fund 

1290 Broadway, Suite 1000 

Denver, Colorado 80203 

(Name and address of agent for service)

 

Registrant’s telephone number, including area code: 877-256-8445

 

Date of fiscal year end: October 31

 

Date of reporting period: November 1, 2019 – October 31, 2020

 

 

Item 1.    Reports to Stockholders.

 

 

Section 19(b) Disclosure

October 31, 2020 (Unaudited)

 

Clough Global Dividend and Income Fund, Clough Global Equity Fund, and Clough Global Opportunities Fund (each a “Fund” and collectively, the “Funds”), acting pursuant to a Securities and Exchange Commission (“SEC”) exemptive order and with the approval of each Fund’s Board of Trustees (the “Board”), have adopted a plan, consistent with each Fund’s investment objectives and policies to support a level distribution of income, capital gains and/or return of capital (the “Plan”). In accordance with the Plan, through December 2019, each Fund paid monthly distributions in an annualized amount of not less than 10% of the respective Fund’s average monthly net asset value (“NAV”). Effective January 1, 2020, the Funds’ managed distribution policy was revised to set the monthly distribution rate at an amount equal to one twelfth of 10% of each Fund’s adjusted year-ending NAV, which is the average of the NAVs as of the last five business days of the prior calendar year. Until July 2021, each Fund will pay monthly distributions in an amount not less than the average distribution rate of a peer group of closed-end funds selected by the Board.

 

Under the Plan, each Fund will distribute all available investment income to its shareholders, consistent with each Fund’s primary investment objectives and as required by the Internal Revenue Code of 1986, as amended (the “Code”). If sufficient investment income is not available on a monthly basis, each Fund will distribute long-term capital gains and/or return of capital to shareholders in order to maintain a level distribution.

 

Each monthly distribution to shareholders is expected to be at the fixed amount established by the Board, except for extraordinary distributions and potential distribution rate increases to enable each Fund to comply with the distribution requirements imposed by the Code.

 

Shareholders should not draw any conclusions about each Fund’s investment performance from the amount of these distributions or from the terms of the Plan. Each Fund’s total return performance on net asset value is presented in its financial highlights table.

 

Until July 2021, each Board may amend, suspend or terminate each Fund’s Plan without prior notice if the Board determines in good faith that continuation would constitute a breach of fiduciary duty or would violate the Investment Company Act of 1940.

 

The suspension or termination of the Plan could have the effect of creating a trading discount (if a Fund’s stock is trading at or above net asset value) or widening an existing trading discount. Each Fund is subject to risks that could have an adverse impact on its ability to maintain level distributions. Examples of potential risks include, but are not limited to, economic downturns impacting the markets, increased market volatility, companies suspending or decreasing corporate dividend distributions and changes in the Code. Please refer to the Notes to Financial Statements in the Annual Report to Shareholders for a more complete description of its risks.

 

Please refer to Additional Information for a cumulative summary of the Section 19(a) notices for each Fund’s current fiscal period. Section 19(a) notices for each Fund, as applicable, are available on the Clough Global Closed-End Funds website www.cloughglobal.com.

 

 

Clough Global Funds Table of Contents
 

 

Shareholder Letter & Portfolio Allocation  
Clough Global Dividend and Income Fund 2
Clough Global Equity Fund 7
Clough Global Opportunities Fund 12
Statement of Investments  
Clough Global Dividend and Income Fund 17
Clough Global Equity Fund 22
Clough Global Opportunities Fund 26
Statements of Assets and Liabilities 31
Statements of Operations 32
Statements of Changes in Net Assets 33
Statements of Cash Flows 36
Financial Highlights  
Clough Global Dividend and Income Fund 38
Clough Global Equity Fund 39
Clough Global Opportunities Fund 40
Notes to Financial Statements 41
Report of Independent Registered Public Accounting Firm 60
Dividend Reinvestment Plan 61
Additional Information  
Fund Proxy Voting Policies & Procedures 62
Portfolio Holdings 62
Notice 62
Shareholder Meeting 62
Section 19(A) Notices 63
Tax Designations 63
Trustees & Officers 64
Summary of Updated Information Regarding Clough Global Dividend and Income Fund 68
Summary of Updated Information Regarding Clough Global Equity Fund 86
Summary of Updated Information Regarding Clough Global Opportunities Fund 103
Privacy Policy 122

 

Beginning on January 1, 2021, as permitted by regulations adopted by the U.S. Securities and Exchange Commission, paper copies of the Funds’ annual and semi-annual shareholder reports will no longer be sent by mail, unless you specifically request paper copies of the reports. Instead, the reports will be made available on the Funds’ website at www.cloughglobal.com, and you will be notified by mail each time a report is posted and provided with a website link to access the report.

 

Beginning on January 1, 2019, you may, notwithstanding the availability of shareholder reports online, elect to receive all future shareholder reports in paper free of charge. If you invest through a financial intermediary, you can contact your financial intermediary to request that you continue to receive paper copies of your shareholder reports. If you invest directly with a Fund, you can call 1-866-226-8017, from 8am to 5pm CT, to let the Fund know you wish to continue receiving paper copies of your shareholder reports.

 

If you already elected to receive shareholder reports electronically, you will not be affected by this change and you need not take any action. You may elect to receive shareholder reports and other communications from a Fund electronically anytime by contacting your financial intermediary (such as a broker-dealer or bank) or, if you are a direct investor, by calling 1-866-226-8017.

 

 

Clough Global Dividend and Income Fund Shareholder Letter
 

October 31, 2020 (Unaudited)

 

For the fiscal year ending October 31, 2020, the Clough Global Dividend and Income Fund (“GLV” or the “Fund”) was down -4.75% on net asset value (“NAV”) and down -9.59% on market price. The Fund’s benchmark, 50% MSCI World Index/50% Bloomberg Barclays U.S. Aggregate Bond Index, was up 6.21% for the same period.

 

TOP FIVE CONTRIBUTORS AND DETRACTORS FOR THE YEAR

 

The Fund’s investment in Eurodollar futures as a hedge against a slowing global economy due to the emerging pandemic proved to be the largest contributor to performance for the year. Eurodollar futures, which are a proxy for future central bank policy, allowed the Fund to maintain its long equity book in the turbulent months of February and March while participating in the recovery rally that started in April. The Fund continues to hold this position as an intended hedge against any additional slow down in economic activity from the spread of COVID-19.

 

PennyMac Financial Services Inc., a market dominant originator and servicer of residential and commercial mortgages, was a top contributor that benefited from increased refinance and new buyer activity as mortgage rates reached all time lows. Apple Inc. and Microsoft Corp. made significant gains from the COVID-19 driven shift to a stay at home economy. Finally, MediaTek Inc., a key beneficiary from the development of 5G technology, was also top performer for the fiscal year.

 

Financial stocks were the top detractors for the year. Citigroup Inc., along with mortgage real estate investment trust (“REIT”) PennyMac Mortgage Investment Trust and commercial REIT Ladder Capital Corp., all declined as the markets priced in meaningful losses to the companies’ portfolios due to the sudden collapse in economy from COVID-19 related shutdowns. Finally, as the markets recovered in the spring, hedge positions in a S&P 500 Index exchange traded fund (“ETF”) and options on the S&P 500 Index were also top detractors from performance.

 

ON THE MARKETS: LIQUIDITY SUPPORT FOR EQUITIES IS POSITIVE

 

We are not political experts, but it appears equities have embraced a Biden presidency along with the possibility of a small Republican majority in the Senate and we can understand why. It is widely expected that there will be better coordination between a Biden administration and the Federal Reserve (the “Fed”) in combining monetary and fiscal policies. A Biden administration is expected to push for additional stimulus packages, and we assume will appoint dovish Federal Reserve governors.

 

The coronavirus was more of an exogenous shock to the market than would be a natural recession. There was no credit crisis or banking collapse, nor was there a profit hit from an excessive capacity build which destroys profitability in a key economic sector, like technology in 2000 or housing in 2008. The threat of more infections would likely prolong the policies of monetary ease.

 

The Fed is currently pumping liquidity into a growing economy and if it lives up to its promises of sustaining zero nominal interest rates into 2022 or 2023, the likelihood of higher returns on investment in the economy in 2021 and beyond looks pretty good.

 

In the meantime, investors are positioned defensively, holding $4.5 trillion in money market funds and another $15.7 trillion in short-term deposits. The amount of money sitting at the 90-day rate is close to the nominal gross domestic product (“GDP”). The Fed would like to see that money invested in the economy and is making holding that cash very costly.

 

The Fed is the most critical factor to the markets. Financial conditions are incredibly favorable, earnings expectations are rising, and the Fed continues to add reserves to the banking system. All of that is positive for equities.

 

Finally, businesses continue to generate large amounts of cash flow according to Bloomberg. Because business investment has been well below that spent in previous business expansions, businesses did not over invest, and excess capacity was never built, so pricing and profitability have held up. With the Pfizer vaccine likely to begin distribution over the next few months, we believe 2021 could be a very strong year for equities.

 

TECHNOLOGY

 

Looking ahead through the 2020s, we believe that the global buildout of 5G telecommunications networks will be a significant investment opportunity. All of the imaginative projects of the 2020s such as autonomous driving, machine learning and the “Internet of Things” require 5G technology. The 5G rollout accelerated with Apple’s announcement of a suite of its 5G equipped iPhones, which promise faster download and upload speeds, higher latency, and quality video gaming and streaming as enticements to buy the phones. Consumer spending is being diverted from travel and leisure to consumer electronics and evidence is mounting that affluent consumers will buy high-end phones. So far, 5G is widely available only in the Asia Pacific region, but where it is available selling prices are 15-20% higher than those of 4G equipped phones. Even in areas where 5G is not available, new phones are selling at a 7% premium to earlier generations.

 

 

2 www.cloughglobal.com

 

 

Clough Global Dividend and Income Fund Shareholder Letter

 

October 31, 2020 (Unaudited)

 

Hundreds of billions of dollars will be spent building out 5G, and competition will be intense, particularly among service providers and companies which build the commodity portions of the infrastructure. To be competitive, service providers will be forced to overbuild their networks ahead of demand and to discount their products to fill capacity. Handset manufacturers without the strong applications businesses which lock in customers, unlike Apple which does, will also have to price aggressively to sell their products. A move to a new standard could add $50-100 per phone to the materials bill, especially for radio frequency (“RF”) chips, processing power and added memory. High-end phone modems must be able to work with any phone in any market and that is expensive. For example, the cost of the modem alone in 5G can increase by more than 50%. So, it is necessary to answer the question: who will capture the profits?

 

Higher materials costs mean more 5G dollars will go to the supply chain companies which solve the bottlenecks, the parts of the networks where proprietary technology breakthroughs are critical to making 5G work. The semiconductor companies with the technologies that solve those problems will not only capture a larger percentage of the phone’s value, but also should lock in the highest profit margins.

 

A major barrier to entry in semiconductor manufacturing is a sharp rise in the capital intensity of component manufacturing. Taiwan Semiconductor Manufacturing Co Ltd. (“TSMC”), a current holding in the Fund, is expected to invest $130 billion through 2030 for high-end foundries for processor chips, an area where the company is already dominant. As capital intensity in the semiconductor industry rises, TSMC gains scale from share gains, and assumes pricing power and market share. Its foundry capacity is ten times that of Samsung’s and Chinese foundries barely compete in the space. TSMC has leading edge semiconductor design and production to the point that the company has already captured the leadership in processors from Intel Corp., and it already produces 20% of Intel’s sales. TSMC, with the industry’s first five nanometer A14 bionic chip, will provide the processors for all of Apple’s models offering speeds of up to 50% faster. Yet the stock has underperformed, and we believe it is relatively inexpensive.

 

We have particularly focused on companies that make up the Apple supply chain. For example, Skyworks Solutions Inc. is a manufacturer of RF chips whose products might be expected to capture a larger percentage of the iPhone’s revenues. Prior to 4G, radio frequency content per phone was about $10 for each smartphone. That rose to $20-30 per phone for 4G and will likely reach $35-40 for each 5G phone. Approximately 50% of the company’s revenues are from Apple.

 

Samsung Electronics Co Ltd. is also a current holding in the Fund. In memory and non-memory chips, the company has unexcelled research and development (“R&D”) and only trails Huawei Technologies Co Ltd. in announced patents. Now the company is making inroads into the manufacturing of 5G infrastructure, including high-end image sensors and foundry capacity. Its share of the telecom market, once a modest 4% or so for 4G, has risen to 10-15% for 5G. Not only is the company picking up on Huawei’s decline, but it has a secure supply chain located in Vietnam and South Korea. It has little China exposure and has far stronger R&D than either LM Ericsson or Nokia Oyj. The company successfully picked up a key Verizon 5G contract to supply 5G radio access equipment through 2025. Yet the stock sells at roughly book value, 11x 2021 earnings per share, offers a 3.5% yield, and its roughly $300 billion market capitalization includes $94 billion in cash.

 

HEALTHCARE

 

COVID-19 has created significant business opportunities for innovative healthcare companies, but a successful vaccine may not be the only positive advancement. In our view, telemedicine and pharmaceutical testing may actually present some of the best long-term profit opportunities. COVID-19 accelerated the shift to telemedicine from in-office visits and the convertible bond of Teladoc Health Inc., the largest company in the telemedicine space, is a current holding in the Fund. Meanwhile, testing is becoming one of the fastest growing sectors in healthcare. We think the market underappreciates the critical role testing companies will continue to play, even with a vaccine approval. The Fund’s testing-related holdings include Thermo Fisher Scientific Inc. and Quest Diagnostics Inc. It should also be noted that Thermo Fisher is one of the leading providers of the refrigeration services that will be required to store COVID-19 vaccines.

 

HOUSING AND MORTGAGE CYCLE

 

Financials are currently selling at low price to earnings ratios and a steeper yield curve would provide a strong tailwind for banks, mortgage REITs, and mortgage servicing companies, many of which sell below book value. Low money rates out to 2023 set up a good backdrop for strong profit margins in the business of agency holdings and credit, the fuel for profit growth among REITs. The Fed’s constant purchasing of mortgage-backed assets sustains the value of REIT holdings and the Fed’s low money rate policies set up a profit margin sweet spot for REITs which own mostly agency paper and mortgages.

 

U.S. housing and the mortgage markets which finance it are booming, yet the stocks of companies that originate and service mortgages and the title insurers sell at a depressed 5-7 times earnings. That would be a reasonable valuation if the housing cycle was peaking but at the beginning of a cycle that could last years, we think both earnings and the multiples on those earnings can rise in the years ahead. Current demand is strong, and land purchased by builders is being immediately developed, not stockpiled for speculative purposes. Millennials, after years of hesitancy, are migrating from parents’ basements and beehive apartments to single-family residences. Supply will struggle to meet that demand. New building has been depressed for a decade and the baby boomers, who own 60% of the housing stock, are not moving. Since 90% of supply comes from existing homes, new construction will have to provide most of the new supply.

 

 
Annual Report | October 31, 2020 3

 

 

Clough Global Dividend and Income Fund Shareholder Letter

 

October 31, 2020 (Unaudited)

 

FIXED INCOME

 

We continue to believe that a low interest rate world will continue to persist for the foreseeable future. We find duration an attractive hedge for the long equity book as well as a potential opportunity to produce positive returns. The Fund continues to hold long duration U.S. Treasuries as well as 10- to 30-year highly rated corporate bonds in sectors that are not adversely impacted by the pandemic.

 

CORPORATE UPDATE

 

By way of a team update, we are very pleased to announce that Dr. Noelle Tune, M.D. has joined Clough Capital Partners L.P. ("Clough Capital") as a Director. Noelle earned her B.A. from Harvard College where she was captain of the women’s crew team. She graduated from medical school at University of North Carolina Chapel Hill before completing her residency at Indiana University, where she was a Chief Resident. Importantly, Mike Hearle worked directly with Dr. Tune in equity research at what is now SVB Leerink from 2000-2004 and has seen the quality of her analysis firsthand. She is an accomplished equity analyst in her own right with a unique combination of talents and is a timely addition to our research efforts. Most recently, Noelle has been on the frontline of the fight against COVID-19 in her capacity as an emergency medicine physician at a high-volume urban health center where she has treated countless patients infected with the virus. Dr. Tune will focus on covering public and private investments in the therapeutics and services areas.

 

As always, please don’t hesitate to reach out to us with any questions or comments.

 

Sincerely,

 

 

Charles I Clough, Jr.

 

 

Robert M. Zdunczyk

 

This letter is provided for informational purposes only and is not an offer to purchase or sell shares. Clough Global Dividend and Income Fund (the “Fund”) is a closed-end fund, which is traded on the NYSE American LLC, and does not continuously issue shares for sale as open-end mutual funds do. The market price of a closed-end fund is based on the market’s value.

 

Although not generally stated throughout, the information in this letter reflects the opinions of the individual portfolio managers, which opinion is subject to change, and is not intended to be a forecast of future events, a guarantee of future results or investment advice.

 

The MSCI World Index is a free float-adjusted market capitalization weighted index that is designed to measure the equity market performance of 23 developed markets countries. Both indices referenced herein reflect the reinvestment of dividends. Effective July 31, 2010, the MSCI World Index returns prior to January 1, 2002 were revised to reflect the total returns, with dividends reinvested, reported by MSCI. The MSCI information may only be used for your internal use, may not be reproduced or redisseminated in any form and may not be used as a basis for or a component of any financial instruments or products or indices. None of the MSCI information is intended to constitute investment advice or a recommendation to make (or refrain from making) any kind of investment decision and may not be relied on as such. Historical data and analysis should not be taken as an indication or guarantee of any future performance analysis, forecast or prediction. The MSCI information is provided on an “as is” basis and the user of this information assumes the entire risk of any use made of this information. MSCI, each of its affiliates and each other person involved in or related to compiling, computing or creating any MSCI information (collectively, the “MSCI Parties”) expressly disclaims all warranties (including, without limitation, any warranties of originality, accuracy, completeness, timeliness, non-infringement, merchantability and fitness for a particular purpose) with respect to this information. Without limiting any of the foregoing, in no event shall any MSCI Party have any liability for any direct, indirect, special, incidental, punitive, consequential (including, without limitation, lost profits) or any other damages (www.msci.com).

 

 

4 www.cloughglobal.com

 

 

Clough Global Dividend and Income Fund Shareholder Letter

 

October 31, 2020 (Unaudited)

 

The Bloomberg Barclays US Aggregate Bond Index measures the performance of the U.S. investment grade bond market. The Barclays Aggregate Bond index invests in a wide spectrum of public, investment-grade, taxable, fixed income securities in the United States, including government, corporate, and international dollar-denominated bonds, as well as mortgage-backed and asset-backed securities, all with maturities of more than 1 year.

 

The performance of the indices referenced herein is used for informational purposes only. One cannot invest directly in an index. Indices are not subject to any of the fees or expenses to which the Fund is subject, and there are significant differences between the Fund’s investments and the components of the indices referenced.

 

The net asset value (NAV) of a closed-end fund is the market price of the underlying investments (i.e., stocks and bonds) in the fund’s portfolio, minus liabilities, divided by the total number of fund shares outstanding. However, the fund also has a market price; the value of which it trades on an exchange. This market price can be more or less than its NAV.

 

RISKS  

An investor should consider investment objectives, risks, charges and expenses carefully before investing. To obtain an annual report or semiannual report which contains this and other information visit www.cloughglobal.com or call 1-877-256-8445. Read them carefully before investing.

 

A Fund’s distribution policy will, under certain circumstances, have certain adverse consequences to the Fund and its shareholders because it may result in a return of capital resulting in less of a shareholder’s assets being invested in the Fund and, over time, increase the Fund’s expense ratio.

 

Distributions may be paid from sources of income other than ordinary income, such as net realized short-term capital gains, net realized long-term capital gains and return of capital. Based on current estimates, we anticipate the most recent distribution has been paid from short-term and longterm capital gains. The actual amounts and sources of the amounts for tax reporting purposes will depend upon a Fund’s investment experience during the remainder of its fiscal year and may be subject to changes based on tax regulations. If a distribution includes anything other than net investment income, the Fund provides a Section 19(a) notice of the best estimate of its distribution sources at that time. These estimates may not match the final tax characterization (for the full year’s distributions) contained in shareholders’ 1099-DIV forms after the end of the year.

 

A Fund’s investments in securities of foreign issuers are subject to risks not usually associated with owning securities of U.S. issuers. These risks can include fluctuations in foreign currencies, foreign currency exchange controls, social, political and economic instability, differences in securities regulation and trading, expropriation or nationalization of assets, and foreign taxation issues.

 

A Fund’s investments in preferred stocks and bonds of below investment grade quality (commonly referred to as “high yield” or “junk bonds”), if any, are predominately speculative because of the credit risk of their issuers.

 

An investment by a Fund in REITs will subject it to various risks. The first, real estate industry risk, is the risk that the REIT share prices will decline because of adverse developments affecting the real estate industry and real property values. In general, real estate values can be affected by a variety of factors, including supply and demand for properties, the economic health of the country or of different regions, and the strength of specific industries that rent properties. The second, investment style risk, is the risk that returns from REITs—which typically are small or medium capitalization stocks—will trail returns from the overall stock market. The third, interest rate risk, is the risk that changes in interest rates may hurt real estate values or make REIT shares less attractive than other income-producing investments. Credit risk is the risk that an issuer of a preferred or debt security will become unable to meet its obligation to make dividend, interest and principal payments.

 

Interest rate risk is the risk that preferred stocks paying fixed dividend rates and fixed-rate debt securities will decline in value because of changes in market interest rates. When interest rates rise the value of such securities generally will fall. Derivative transactions (such as futures contracts and options thereon, options, swaps, and short sales) subject a Fund to increased risk of principal loss due to imperfect correlation or unexpected price or interest rate movements. Compared to investment companies that focus only on large companies, the Fund’s share price may be more volatile because it also invests in small and medium capitalization companies.

 

Past performance is neither a guarantee, nor necessarily indicative, of future results, which may be significantly affected by changes in economic and other conditions.

 

 

Annual Report | October 31, 2020 5

 

 

Clough Global Dividend and Income Fund Portfolio Allocation
 

  October 31, 2020 (Unaudited)

 

Top 10 Equity Holdings(a)(d) % of Total Portfolio
1. PennyMac Financial Services, Inc. 5.19%
2. Quest Diagnostics, Inc. 4.35%
3. Apple, Inc. 4.14%
4. Community Healthcare Trust, Inc. 4.09%
5. Microsoft Corp. 3.82%
6. Taiwan Semiconductor Manufacturing Co., Ltd. 2.53%
7. First American Financial Corp. 2.48%
8. Annaly Capital Management, Inc. 2.43%
9. Sany Heavy Industry Co., Ltd. 2.27%
10. AGNC Investment Corp. 2.06%

 

Global Securities Holdings(a) % of Total Portfolio
United States 78.61%
U.S. Multinationals(b) 11.29%
China 6.20%
Taiwan 2.53%
Hong Kong 2.14%
South Korea 0.74%
Switzerland 0.05%
Other -1.57%
TOTAL INVESTMENTS 100.00%
Asset Allocation(a) % of Total Portfolio
Common Stock - US 37.03%
Common Stock - Foreign 14.93%
Total Return Swap Contracts 3.98%
Total Equities 55.94%
   
Government L/T 21.24%
Corporate Debt 14.22%
Preferred Stock 0.85%
Municipal Bond 0.59%
Asset-Backed Securities 0.05%
Total Fixed Income 36.95%
   
Short-Term Investments 3.15%
Futures 1.80%
Other (Cash) 1.66%
Purchased Options 0.50%
   
TOTAL INVESTMENTS 100.00%

 

Country Allocation(c) Long
Exposure
%TNA
Short
Exposure
%TNA
Gross
Exposure
%TNA
Net
Exposure
%TNA
United States 121.5% -2.6% 124.1% 118.9%
U.S. Multinationals(b) 22.2% -5.1% 27.3% 17.1%
China 9.4% 0.0% 9.4% 9.4%
Taiwan 3.8% 0.0% 3.8% 3.8%
Hong Kong 3.2% 0.0% 3.2% 3.2%
South Korea 1.1% 0.0% 1.1% 1.1%
Switzerland 0.7% -0.6% 1.3% 0.1%
Other 0.8% -3.1% 3.9% -2.3%
TOTAL INVESTMENTS 162.7% -11.5% 174.1% 151.3%

 

(a) Percentages calculated based on total portfolio, including securities sold short, cash balances, market value of futures, and notional value of return swaps.
(b) U.S. Multinationals includes companies organized or located in the United States that have more than 50% of revenues derived outside of the United States.
(c) Percentages calculated based on the net asset value of the Fund.
(d) Only long equity and equity-related positions are listed.


 
6 www.cloughglobal.com

 

 

Clough Global Equity Fund Shareholder Letter

 

October 31, 2020 (Unaudited)

 

For the fiscal year ending October 31, 2020, the Clough Global Equity Fund (“GLQ” or the “Fund”) was up 11.55% on net asset value (“NAV”) and up 3.21% on market price. The Fund’s benchmark, the MSCI World Index, was up 4.95% for the same period.

 

TOP FIVE CONTRIBUTORS AND DETRACTORS FOR THE YEAR

 

The Fund’s investment in Eurodollar futures as a hedge against a slowing global economy due to the emerging pandemic proved to be the largest contributor to performance for the year. Eurodollar futures, which are a proxy for future central bank policy, allowed the fund to maintain its long equity book in the turbulent months of February and March while participating in the recovery rally that started in April. The Fund continues to hold this position as an intended hedge against any additional slow down in economic activity from the spread of COVID-19.

 

PennyMac Financial Services Inc., a market dominant originator and servicer of residential and commercial mortgages, was a top contributor that benefited from increased refinance and new buyer activity as mortgage rates reached all time lows. Amazon.com Inc. and Netflix Inc. made significant gains from the COVID-19 driven shift to a stay at home economy. Finally, CRISPR Therapeutics, the leading company in the gene editing space, performed well as the company made progress in its oncology, beta thalassemia and sickle cell therapies.

 

Financial stocks were the top detractors for the year. Citigroup Inc., along with mortgage real estate investment trust (“REIT”) PennyMac Mortgage Investment Trust, Ladder Capital Corp. and Two Harbors Investment Corp., all declined as the markets priced in meaningful losses to the companies’ portfolios due to the sudden collapse in economy from COVID-19 related shutdowns. Finally, as the markets recovered in the spring, a hedge position in a S&P 500 Index exchange traded fund (“ETF”) was also top detractor from performance.

 

ON THE MARKETS: LIQUIDITY SUPPORT FOR EQUITIES IS POSITIVE

 

We are not political experts, but it appears equities have embraced a Biden presidency along with the possibility of a small Republican majority in the Senate and we can understand why. It is widely expected that there will be better coordination between a Biden administration and the Federal Reserve (the “Fed”) in combining monetary and fiscal policies. A Biden administration is expected to push for additional stimulus packages, and we assume will appoint dovish Federal Reserve governors.

 

The coronavirus was more of an exogenous shock to the market than would be a natural recession. There was no credit crisis or banking collapse, nor was there a profit hit from an excessive capacity build which destroys profitability in a key economic sector, like technology in 2000 or housing in 2008. The threat of more infections would likely prolong the policies of monetary ease.

 

The Fed is currently pumping liquidity into a growing economy and if it lives up to its promises of sustaining zero nominal interest rates into 2022 or 2023, the likelihood of higher returns on investment in the economy in 2021 and beyond looks pretty good.

 

In the meantime, investors are positioned defensively, holding $4.5 trillion in money market funds and another $15.7 trillion in short-term deposits. The amount of money sitting at the 90-day rate is close to the nominal gross domestic product (“GDP”). The Fed would like to see that money invested in the economy and is making holding that cash very costly.

 

The Fed is the most critical factor to the markets. Financial conditions are incredibly favorable, earnings expectations are rising, and the Fed continues to add reserves to the banking system. All of that is positive for equities.

 

Finally, businesses continue to generate large amounts of cash flow according to Bloomberg. Because business investment has been well below that spent in previous business expansions, businesses did not over invest, and excess capacity was never built, so pricing and profitability have held up. With the Pfizer vaccine likely to begin distribution over the next few months, we believe 2021 could be a very strong year for equities.

 

POSITIONING FOR 2021

 

The majority of the Fund’s current long exposure is focused in the high free cash flow generating sectors of technology and healthcare in the United States as well as in China. The Fund is also set up to potentially benefit from what we believe will be a long-lasting housing cycle in the U.S.

 

TECHNOLOGY

 

Looking ahead through the 2020s, we believe that the global buildout of 5G telecommunications networks will be a significant investment opportunity. All of the imaginative projects of the 2020s such as autonomous driving, machine learning and the “Internet of Things” require 5G technology. The 5G rollout accelerated with Apple’s announcement of a suite of its 5G equipped iPhones, which promise faster download and upload speeds, higher latency, and quality video gaming and streaming as enticements to buy the phones. Consumer spending is being diverted from travel and leisure to consumer electronics and evidence is mounting that affluent consumers will buy high-end phones. So far, 5G is widely available only in the Asia Pacific region, but where it is available selling prices are 15-20% higher than those of 4G equipped phones. Even in areas where 5G is not available, new phones are selling at a 7% premium to earlier generations.

 

 
Annual Report | October 31, 2020 7

 

 

Clough Global Equity Fund Shareholder Letter

 

October 31, 2020 (Unaudited)

 

Hundreds of billions of dollars will be spent building out 5G, and competition will be intense, particularly among service providers and companies which build the commodity portions of the infrastructure. To be competitive, service providers will be forced to overbuild their networks ahead of demand and to discount their products to fill capacity. Handset manufacturers without the strong applications businesses which lock in customers, unlike Apple which does, will also have to price aggressively to sell their products. A move to a new standard could add $50-100 per phone to the materials bill, especially for radio frequency (“RF”) chips, processing power and added memory. High-end phone modems must be able to work with any phone in any market and that is expensive. For example, the cost of the modem alone in 5G can increase by more than 50%. So, it is necessary to answer the question: who will capture the profits?

 

Higher materials costs mean more 5G dollars will go to the supply chain companies which solve the bottlenecks, the parts of the networks where proprietary technology breakthroughs are critical to making 5G work. The semiconductor companies with the technologies that solve those problems will not only capture a larger percentage of the phone’s value, but also should lock in the highest profit margins.

 

A major barrier to entry in semiconductor manufacturing is a sharp rise in the capital intensity of component manufacturing. Taiwan Semiconductor Manufacturing Co Ltd. (“TSMC”), a current holding in the Fund, is expected to invest $130 billion through 2030 for high-end foundries for processor chips, an area where the company is already dominant. As capital intensity in the semiconductor industry rises, TSMC gains scale from share gains, and assumes pricing power and market share. Its foundry capacity is ten times that of Samsung’s and Chinese foundries barely compete in the space. TSMC has leading edge semiconductor design and production to the point that the company has already captured the leadership in processors from Intel Corp., and it already produces 20% of Intel’s sales. TSMC, with the industry’s first five nanometer A14 bionic chip, will provide the processors for all of Apple’s models offering speeds of up to 50% faster. Yet the stock has underperformed, and we believe it is relatively inexpensive.

 

We have particularly focused on companies that make up the Apple supply chain. For example, Skyworks Solutions Inc. is a manufacturer of RF chips whose products might be expected to capture a larger percentage of the iPhone’s revenues. Prior to 4G, radio frequency content per phone was about $10 for each smartphone. That rose to $20-30 per phone for 4G and will likely reach $35-40 for each 5G phone. Approximately 50% of the company’s revenues are from Apple.

 

Samsung Electronics Co Ltd. is also a current holding in the Fund. In memory and non-memory chips, the company has unexcelled research and development (“R&D”) and only trails Huawei Technologies Co Ltd. in announced patents. Now the company is making inroads into the manufacturing of 5G infrastructure, including high-end image sensors and foundry capacity. Its share of the telecom market, once a modest 4% or so for 4G, has risen to 10-15% for 5G. Not only is the company picking up on Huawei’s decline, but it has a secure supply chain located in Vietnam and South Korea. It has little China exposure and has far stronger R&D than either LM Ericsson or Nokia Oyj. The company successfully picked up a key Verizon 5G contract to supply 5G radio access equipment through 2025. Yet the stock sells at roughly book value, 11x 2021 earnings per share, offers a 3.5% yield, and its roughly $300 billion market capitalization includes $94 billion in cash.

 

HEALTHCARE

 

In our view, health sciences will be one of the fastest growing areas of spending in the 2020s. Investors have been jittery since Hillary Clinton, as a presidential candidate in 2015, pushed price controls for big pharma and biotech. Since then, tens of billions of R&D dollars have been spent developing new therapies and huge strides have been made in medical discoveries and genomics. Many of those therapies are now entering human trials and that is the point at which value can be created for many companies. The industry offers the cheapest source of R&D in the securities markets. There are three ways to monetize this as we currently see it:

 

1. We anticipate a pickup in mergers and acquisitions (“M&A”). Only three deals were announced in the first half of 2020. In the third quarter, Gilead Sciences Inc. offered $21 billion for Immunomedics Inc. and Johnson and Johnson offered $6.5 billion for Momenta Pharmaceuticals Inc. We believe there exists significant pent-up demand at large pharma companies for attractive pipeline assets. The Fund is invested in potential biotechnology M&A targets that we believe generally have strong management teams, that have sold companies in the past, possess solid intellectual property, and disruptive technologies and attractive therapeutic focuses (e.g., oncology and rare diseases).

 

2. COVID-19 has created significant business opportunities for innovative healthcare companies, but a successful vaccine may not be the only positive advancement. In our view, telemedicine and pharmaceutical testing may actually present some of the best long-term profit opportunities. COVID-19 accelerated the shift to telemedicine from in-office visits and Teladoc Health Inc., the largest company in the telemedicine space, is a current holding in the Fund. Meanwhile, testing is becoming one of the fastest growing sectors in healthcare. We think the market underappreciates the critical role testing companies will continue to play, even with a vaccine approval. The Fund’s testing-related holdings include Hologic Inc., Thermo Fisher Scientific Inc., and Quest Diagnostics Inc. It should also be noted that Thermo Fisher is a leading producer of the refrigeration required for newly announced COVID-19 vaccines.

 

 

8 www.cloughglobal.com

 

 

Clough Global Equity Fund Shareholder Letter

 

October 31, 2020 (Unaudited)

 

3. Additional core holdings include CRISPR Therapeutics, which made further progress demonstrating clinical progress in sickle cell disease, beta thalassemia and solid tumor trials and has partnered with Vertex Pharmaceuticals Inc. in a series of oncology trials. CRISPR has resumed dosing hemophilia patients for phase 1/2 trials and patients have remained blood transfusion free for 15, 9 and 5 months which are highly encouraging outcomes. On the oncology front, where the company fully owns its intellectual property, the company presented initial data for its phase 1-2 allogeneic CAR-T trial showing excellent activity and outcomes in this tough to treat population.

 

HOUSING AND MORTGAGE CYCLE

 

Financials are currently selling at low price to earnings ratios and a steeper yield curve would provide a strong tailwind for banks, mortgage REITs, and mortgage servicing companies, many of which sell below book value. Low money rates out to 2023 set up a good backdrop for strong profit margins in the business of agency holdings and credit, the fuel for profit growth among REITs. The Fed’s constant purchasing of mortgage-backed assets sustains the value of REIT holdings and the Fed’s low money rate policies set up a profit margin sweet spot for REITs which own mostly agency paper and mortgages.

 

U.S. housing and the mortgage markets which finance it are booming, yet the stocks of companies that originate and service mortgages and the title insurers sell at a depressed 5-7 times earnings. That would be a reasonable valuation if the housing cycle was peaking but at the beginning of a cycle that could last years, we think both earnings and the multiples on those earnings can rise in the years ahead. Current demand is strong, and land purchased by builders is being immediately developed, not stockpiled for speculative purposes. Millennials, after years of hesitancy, are migrating from parents’ basements and beehive apartments to single-family residences. Supply will struggle to meet that demand. New building has been depressed for a decade and the baby boomers, who own 60% of the housing stock, are not moving. Since 90% of supply comes from existing homes, new construction will have to provide most of the new supply.

 

CORPORATE UPDATE

 

By way of a team update, we are very pleased to announce that Dr. Noelle Tune, M.D. has joined Clough Capital Partners L.P. ("Clough Capital") as a Director. Noelle earned her B.A. from Harvard College where she was captain of the women’s crew team. She graduated from medical school at University of North Carolina Chapel Hill before completing her residency at Indiana University, where she was a Chief Resident. Importantly, Mike Hearle worked directly with Dr. Tune in equity research at what is now SVB Leerink from 2000-2004 and has seen the quality of her analysis firsthand. She is an accomplished equity analyst in her own right with a unique combination of talents and is a timely addition to our research efforts. Most recently, Noelle has been on the frontline of the fight against COVID-19 in her capacity as an emergency medicine physician at a high-volume urban health center where she has treated countless patients infected with the virus. Dr. Tune will focus on covering public and private investments in the therapeutics and services areas.

 

As always, please don’t hesitate to reach out to us with any questions or comments.

 

Sincerely,

 

Charles I Clough, Jr.

 

 

Robert M. Zdunczyk

 

This letter is provided for informational purposes only and is not an offer to purchase or sell shares. Clough Global Equity Fund (the “Fund”) is a closed-end fund, which is traded on the NYSE American LLC, and does not continuously issue shares for sale as open-end mutual funds do. The market price of a closed-end fund is based on the market’s value.

 

Although not generally stated throughout, the information in this letter reflects the opinions of the individual portfolio managers, which opinion is subject to change, and is not intended to be a forecast of future events, a guarantee of future results or investment advice.

 

 
Annual Report | October 31, 2020 9

 

 

Clough Global Equity Fund Shareholder Letter

 

October 31, 2020 (Unaudited)

 

The MSCI World Index is a free float-adjusted market capitalization weighted index that is designed to measure the equity market performance of 23 developed markets countries. Both indices referenced herein reflect the reinvestment of dividends. Effective July 31, 2010, the MSCI World Index returns prior to January 1, 2002 were revised to reflect the total returns, with dividends reinvested, reported by MSCI. The MSCI information may only be used for your internal use, may not be reproduced or redisseminated in any form and may not be used as a basis for or a component of any financial instruments or products or indices. None of the MSCI information is intended to constitute investment advice or a recommendation to make (or refrain from making) any kind of investment decision and may not be relied on as such. Historical data and analysis should not be taken as an indication or guarantee of any future performance analysis, forecast or prediction. The MSCI information is provided on an “as is” basis and the user of this information assumes the entire risk of any use made of this information. MSCI, each of its affiliates and each other person involved in or related to compiling, computing or creating any MSCI information (collectively, the “MSCI Parties”) expressly disclaims all warranties (including, without limitation, any warranties of originality, accuracy, completeness, timeliness, non-infringement, merchantability and fitness for a particular purpose) with respect to this information. Without limiting any of the foregoing, in no event shall any MSCI Party have any liability for any direct, indirect, special, incidental, punitive, consequential (including, without limitation, lost profits) or any other damages (www.msci.com).

 

The performance of the indices referenced herein is used for informational purposes only. One cannot invest directly in an index. Indices are not subject to any of the fees or expenses to which the Fund is subject, and there are significant differences between the Fund’s investments and the components of the indices referenced.

 

The net asset value (NAV) of a closed-end fund is the market price of the underlying investments (i.e., stocks and bonds) in the fund’s portfolio, minus liabilities, divided by the total number of fund shares outstanding. However, the fund also has a market price; the value of which it trades on an exchange. This market price can be more or less than its NAV.

 

RISKS 

An investor should consider investment objectives, risks, charges and expenses carefully before investing. To obtain an annual report or semiannual report which contains this and other information visit www.cloughglobal.com or call 1-877-256-8445. Read them carefully before investing.

 

A Fund’s distribution policy will, under certain circumstances, have certain adverse consequences to the Fund and its shareholders because it may result in a return of capital resulting in less of a shareholder’s assets being invested in the Fund and, over time, increase the Fund’s expense ratio.

 

Distributions may be paid from sources of income other than ordinary income, such as net realized short-term capital gains, net realized long-term capital gains and return of capital. Based on current estimates, we anticipate the most recent distribution has been paid from short-term and longterm capital gains. The actual amounts and sources of the amounts for tax reporting purposes will depend upon a Fund’s investment experience during the remainder of its fiscal year and may be subject to changes based on tax regulations. If a distribution includes anything other than net investment income, the Fund provides a Section 19(a) notice of the best estimate of its distribution sources at that time. These estimates may not match the final tax characterization (for the full year’s distributions) contained in shareholders’ 1099-DIV forms after the end of the year.

 

A Fund’s investments in securities of foreign issuers are subject to risks not usually associated with owning securities of U.S. issuers. These risks can include fluctuations in foreign currencies, foreign currency exchange controls, social, political and economic instability, differences in securities regulation and trading, expropriation or nationalization of assets, and foreign taxation issues.

 

A Fund’s investments in preferred stocks and bonds of below investment grade quality (commonly referred to as “high yield” or “junk bonds”), if any, are predominately speculative because of the credit risk of their issuers.

 

An investment by a Fund in REITs will subject it to various risks. The first, real estate industry risk, is the risk that the REIT share prices will decline because of adverse developments affecting the real estate industry and real property values. In general, real estate values can be affected by a variety of factors, including supply and demand for properties, the economic health of the country or of different regions, and the strength of specific industries that rent properties. The second, investment style risk, is the risk that returns from REITs—which typically are small or medium capitalization stocks—will trail returns from the overall stock market. The third, interest rate risk, is the risk that changes in interest rates may hurt real estate values or make REIT shares less attractive than other income-producing investments. Credit risk is the risk that an issuer of a preferred or debt security will become unable to meet its obligation to make dividend, interest and principal payments.

 

Interest rate risk is the risk that preferred stocks paying fixed dividend rates and fixed-rate debt securities will decline in value because of changes in market interest rates. When interest rates rise the value of such securities generally will fall. Derivative transactions (such as futures contracts and options thereon, options, swaps, and short sales) subject a Fund to increased risk of principal loss due to imperfect correlation or unexpected price or interest rate movements. Compared to investment companies that focus only on large companies, the Fund’s share price may be more volatile because it also invests in small and medium capitalization companies.

 

Past performance is neither a guarantee, nor necessarily indicative, of future results, which may be significantly affected by changes in economic and other conditions.

 

 

10 www.cloughglobal.com

 

 

Clough Global Equity Fund Portfolio Allocation

 

October 31, 2020 (Unaudited)

 

Top 10 Equity Holdings(a)(d) % of Total Portfolio
1. PennyMac Financial Services, Inc. 4.69%
2. First American Financial Corp. 2.64%
3. Taiwan Semiconductor Manufacturing Co., Ltd. 2.47%
4. Quest Diagnostics, Inc. 2.46%
5. Apple, Inc. 2.37%
6. Annaly Capital Management, Inc. 2.34%
7. AGNC Investment Corp. 2.32%
8. Hologic, Inc. 2.18%
9. Amazon.com, Inc. 1.95%
10. Sany Heavy Industry Co., Ltd. 1.90%

 

Global Securities Holdings(a) % of Total Portfolio
United States 71.94%
U.S. Multinationals(b) 11.83%
China 9.39%
Taiwan 2.47%
Switzerland 1.77%
Hong Kong 1.26%
United Kingdom 1.14%
Canada 0.98%
Japan 0.58%
Other -1.37%
TOTAL INVESTMENTS 100.00%
Asset Allocation(a) % of Total Portfolio
Common Stock - US 56.44%
Common Stock - Foreign 22.76%
Total Return Swap Contracts 5.03%
Total Equities 84.23%
   
Government L/T 10.16%
Total Fixed Income 10.16%
   
Other (Cash) 1.78%
Futures 1.63%
Short-Term Investments 1.31%
Purchased Options 0.89%
   
TOTAL INVESTMENTS 100.00%

 

Country Allocation(c)

Long 

Exposure 

%TNA 

Short 

Exposure 

%TNA 

Gross 

Exposure 

%TNA 

Net 

Exposure 

%TNA 

United States 109.7% -2.5% 112.2% 107.2%
U.S. Multinationals(b) 22.5% -4.8% 27.3% 17.7%
China 14.0% 0.0% 14.0% 14.0%
Taiwan 3.7% 0.0% 3.7% 3.7%
Switzerland 3.2% -0.6% 3.8% 2.6%
Hong Kong 1.9% 0.0% 1.9% 1.9%
United Kingdom 1.7% 0.0% 1.7% 1.7%
Canada 1.5% 0.0% 1.5% 1.5%
Japan 0.9% 0.0% 0.9% 0.9%
Other 0.8% -2.8% 3.6% -2.0%
TOTAL INVESTMENTS 159.9% -10.7% 170.6% 149.2%

 

(a) Percentages calculated based on total portfolio, including securities sold short, cash balances, market value of futures, and notional value of return swaps.

(b) U.S. Multinationals includes companies organized or located in the United States that have more than 50% of revenues derived outside of the United States.

(c) Percentages calculated based on the net asset value of the Fund.

(d) Only long equity and equity-related positions are listed.


 

Annual Report | October 31, 2020 11

 

 

Clough Global Opportunities Fund Shareholder Letter

 

October 31, 2020 (Unaudited)

 

For the fiscal year ending October 31, 2020, the Clough Global Opportunities Fund (“GLO” or the “Fund”) was up 11.91% on net asset value (“NAV”) and up 8.46% on market price. The Fund’s benchmark, 75% MSCI World Index/25% of the Bloomberg Barclay U.S. Aggregate Bond Index, was up 5.73% for the same period.

 

TOP FIVE CONTRIBUTORS AND DETRACTORS FOR THE YEAR

 

The Fund’s investment in Eurodollar futures as a hedge against a slowing global economy due to the emerging pandemic proved to be the largest contributor to performance for the year. Eurodollar futures, which are a proxy for future central bank policy, allowed the Fund to maintain its long equity book in the turbulent months of February and March while participating in the recovery rally that started in April. The Fund continues to hold this position as an intended hedge against any additional slow down in economic activity from the spread of COVID-19.

 

PennyMac Financial Services Inc., a market dominant originator and servicer of residential and commercial mortgages, was a top contributor that benefited from increased refinance and new buyer activity as mortgage rates reached all time lows. Amazon.com Inc. and Teladoc Health Inc., a leading online healthcare provider, made significant gains from the COVID-19 driven shift to a stay at home economy. Finally, CRISPR Therapeutics, the leading company in the gene editing space, performed well as the company made progress in its oncology, beta thalassemia and sickle cell therapies.

 

Financial stocks were the top detractors for the year. Citigroup Inc., along with mortgage real estate investment trust (“REIT”) PennyMac Mortgage Investment Trust and Two Harbors Investment Corp., all declined as the markets priced in meaningful losses to the companies’ portfolios due to the sudden collapse in economy from COVID-19 related shutdowns. Finally, as the markets recovered in the spring, hedge positions in a S&P 500 Index exchange traded fund (“ETF”) and options on the S&P 500 Index were also top detractors from performance.

 

ON THE MARKETS: LIQUIDITY SUPPORT FOR EQUITIES IS POSITIVE

 

We are not political experts, but it appears equities have embraced a Biden presidency along with the possibility of a small Republican majority in the Senate and we can understand why. It is widely expected that there will be better coordination between a Biden administration and the Federal Reserve (the “Fed”) in combining monetary and fiscal policies. A Biden administration is expected to push for additional stimulus packages, and we assume will appoint dovish Federal Reserve governors.

 

The coronavirus was more of an exogenous shock to the market than would be a natural recession. There was no credit crisis or banking collapse, nor was there a profit hit from an excessive capacity build which destroys profitability in a key economic sector, like technology in 2000 or housing in 2008. The threat of more infections would likely prolong the policies of monetary ease.

 

The Fed is currently pumping liquidity into a growing economy and if it lives up to its promises of sustaining zero nominal interest rates into 2022 or 2023, the likelihood of higher returns on investment in the economy in 2021 and beyond looks pretty good.

 

In the meantime, investors are positioned defensively, holding $4.5 trillion in money market funds and another $15.7 trillion in short-term deposits. The amount of money sitting at the 90-day rate is close to the nominal gross domestic product (“GDP”). The Fed would like to see that money invested in the economy and is making holding that cash very costly.

 

The Fed is the most critical factor to the markets. Financial conditions are incredibly favorable, earnings expectations are rising, and the Fed continues to add reserves to the banking system. All of that is positive for equities.

 

Finally, businesses continue to generate large amounts of cash flow according to Bloomberg. Because business investment has been well below that spent in previous business expansions, businesses did not over invest, and excess capacity was never built, so pricing and profitability have held up. With the Pfizer vaccine likely to begin distribution over the next few months, we believe 2021 could be a very strong year for equities.

 

POSITIONING FOR 2021

 

The majority of the Fund’s current long exposure is focused in the high free cash flow generating sectors of technology and healthcare in the United States as well as in China. The Fund is also set up to potentially benefit from what we believe will be a long-lasting housing cycle in the U.S.

 

TECHNOLOGY

 

Looking ahead through the 2020s, we believe that the global buildout of 5G telecommunications networks will be a significant investment opportunity. All of the imaginative projects of the 2020s such as autonomous driving, machine learning and the “Internet of Things” require 5G technology. The 5G rollout accelerated with Apple’s announcement of a suite of its 5G equipped iPhones, which promise faster download and upload speeds, higher latency, and quality video gaming and streaming as enticements to buy the phones. Consumer spending is being diverted from travel and leisure to consumer electronics and evidence is mounting that affluent consumers will buy high-end phones. So far, 5G is widely available only in the Asia Pacific region, but where it is available selling prices are 15-20% higher than those of 4G equipped phones. Even in areas where 5G is not available, new phones are selling at a 7% premium to earlier generations.

 

 

12 www.cloughglobal.com

 

 

Clough Global Opportunities Fund Shareholder Letter

 

October 31, 2020 (Unaudited)

 

Hundreds of billions of dollars will be spent building out 5G, and competition will be intense, particularly among service providers and companies which build the commodity portions of the infrastructure. To be competitive, service providers will be forced to overbuild their networks ahead of demand and to discount their products to fill capacity. Handset manufacturers without the strong applications businesses which lock in customers, unlike Apple which does, will also have to price aggressively to sell their products. A move to a new standard could add $50-100 per phone to the materials bill, especially for radio frequency (“RF”) chips, processing power and added memory. High-end phone modems must be able to work with any phone in any market and that is expensive. For example, the cost of the modem alone in 5G can increase by more than 50%. So, it is necessary to answer the question: who will capture the profits?

 

Higher materials costs mean more 5G dollars will go to the supply chain companies which solve the bottlenecks, the parts of the networks where proprietary technology breakthroughs are critical to making 5G work. The semiconductor companies with the technologies that solve those problems will not only capture a larger percentage of the phone’s value, but also should lock in the highest profit margins.

 

A major barrier to entry in semiconductor manufacturing is a sharp rise in the capital intensity of component manufacturing. Taiwan Semiconductor Manufacturing Co Ltd. (“TSMC”), a current holding in the Fund, is expected to invest $130 billion through 2030 for high-end foundries for processor chips, an area where the company is already dominant. As capital intensity in the semiconductor industry rises, TSMC gains scale from share gains, and assumes pricing power and market share. Its foundry capacity is ten times that of Samsung’s and Chinese foundries barely compete in the space. TSMC has leading edge semiconductor design and production to the point that the company has already captured the leadership in processors from Intel Corp., and it already produces 20% of Intel’s sales. TSMC, with the industry’s first five nanometer A14 bionic chip, will provide the processors for all of Apple’s models offering speeds of up to 50% faster. Yet the stock has underperformed, and we believe it is relatively inexpensive.

 

We have particularly focused on companies that make up the Apple supply chain. For example, Skyworks Solutions Inc. is a manufacturer of RF chips whose products might be expected to capture a larger percentage of the iPhone’s revenues. Prior to 4G, radio frequency content per phone was about $10 for each smartphone. That rose to $20-30 per phone for 4G and will likely reach $35-40 for each 5G phone. Approximately 50% of the company’s revenues are from Apple.

 

Samsung Electronics Co Ltd. is also a current holding in the Fund. In memory and non-memory chips, the company has unexcelled research and development (“R&D”) and only trails Huawei Technologies Co Ltd. in announced patents. Now the company is making inroads into the manufacturing of 5G infrastructure, including high-end image sensors and foundry capacity. Its share of the telecom market, once a modest 4% or so for 4G, has risen to 10-15% for 5G. Not only is the company picking up on Huawei’s decline, but it has a secure supply chain located in Vietnam and South Korea. It has little China exposure and has far stronger R&D than either LM Ericsson or Nokia Oyj. The company successfully picked up a key Verizon 5G contract to supply 5G radio access equipment through 2025. Yet the stock sells at roughly book value, 11x 2021 earnings per share, offers a 3.5% yield, and its roughly $300 billion market capitalization includes $94 billion in cash.

 

HEALTHCARE

 

In our view, health sciences will be one of the fastest growing areas of spending in the 2020s. Investors have been jittery since Hillary Clinton, as a presidential candidate in 2015, pushed price controls for big pharma and biotech. Since then, tens of billions of R&D dollars have been spent developing new therapies and huge strides have been made in medical discoveries and genomics. Many of those therapies are now entering human trials and that is the point at which value can be created for many companies. The industry offers the cheapest source of R&D in the securities markets. There are three ways to monetize this as we currently see it:

 

1. We anticipate a pickup in mergers and acquisitions (“M&A”). Only three deals were announced in the first half of 2020. In the third quarter, Gilead Sciences Inc. offered $21 billion for Immunomedics Inc. and Johnson and Johnson offered $6.5 billion for Momenta Pharmaceuticals Inc. We believe there exists significant pent-up demand at large pharma companies for attractive pipeline assets. The Fund is invested in potential biotechnology M&A targets that we believe generally have strong management teams, that have sold companies in the past, possess solid intellectual property, and disruptive technologies and attractive therapeutic focuses (e.g., oncology and rare diseases).

 

2. COVID-19 has created significant business opportunities for innovative healthcare companies, but a successful vaccine may not be the only positive advancement. In our view, telemedicine and pharmaceutical testing may actually present some of the best long-term profit opportunities. COVID-19 accelerated the shift to telemedicine from in-office visits and Teladoc Health Inc., the largest company in the telemedicine space, is a current holding in the Fund. Meanwhile, testing is becoming one of the fastest growing sectors in healthcare. We think the market underappreciates the critical role testing companies will continue to play, even with a vaccine approval. The Fund’s testing-related holdings include Hologic Inc., Thermo Fisher Scientific Inc., and Quest Diagnostics Inc. It should also be noted that Thermo Fisher is a leading producer of the refrigeration required for newly announced COVID-19 vaccines.

 

 

Annual Report | October 31, 2020 13

 

 

Clough Global Opportunities Fund Shareholder Letter

 

October 31, 2020 (Unaudited)

 

3. Additional core holdings include CRISPR Therapeutics, which made further progress demonstrating clinical progress in sickle cell disease, beta thalassemia and solid tumor trials and has partnered with Vertex Pharmaceuticals Inc. in a series of oncology trials. CRISPR has resumed dosing hemophilia patients for phase 1/2 trials and patients have remained blood transfusion free for 15, 9 and 5 months which are highly encouraging outcomes. On the oncology front, where the company fully owns its intellectual property, the company presented initial data for its phase 1-2 allogeneic CAR-T trial showing excellent activity and outcomes in this tough to treat population.

 

HOUSING AND MORTGAGE CYCLE

 

Financials are currently selling at a low price to earnings ratios and a steeper yield curve would provide a strong tailwind for banks, mortgage REITs, and mortgage servicing companies, many of which sell below book value. Low money rates out to 2023 set up a good backdrop for strong profit margins in the business of agency holdings and credit, the fuel for profit growth among REITs. The Fed’s constant purchasing of mortgage-backed assets sustains the value of REIT holdings and the Fed’s low money rate policies set up a profit margin sweet spot for REITs which own mostly agency paper and mortgages.

 

U.S. housing and the mortgage markets which finance it are booming, yet the stocks of companies that originate and service mortgages and the title insurers sell at a depressed 5-7 times earnings. That would be a reasonable valuation if the housing cycle was peaking but at the beginning of a cycle that could last years, we think both earnings and the multiples on those earnings can rise in the years ahead. Current demand is strong, and land purchased by builders is being immediately developed, not stockpiled for speculative purposes. Millennials, after years of hesitancy, are migrating from parents’ basements and beehive apartments to single-family residences. Supply will struggle to meet that demand. New building has been depressed for a decade and the baby boomers, who own 60% of the housing stock, are not moving. Since 90% of supply comes from existing homes, new construction will have to provide most of the new supply.

 

FIXED INCOME

 

We continue to believe that a low interest rate world will continue to persist for the foreseeable future. We find duration an attractive hedge for the long equity book as well as a potential opportunity to produce positive returns for the Fund’s investors. The Fund continues to hold long duration U.S. Treasuries as well as 10- to 30-year highly rated corporate bonds in sectors that are not adversely impacted by the pandemic.

 

CORPORATE UPDATE

 

By way of a team update, we are very pleased to announce that Dr. Noelle Tune, M.D. has joined Clough Capital Partners L.P. ("Clough Capital") as a Director. Noelle earned her B.A. from Harvard College where she was captain of the women’s crew team. She graduated from medical school at University of North Carolina Chapel Hill before completing her residency at Indiana University, where she was a Chief Resident. Importantly, Mike Hearle worked directly with Dr. Tune in equity research at what is now SVB Leerink from 2000-2004 and has seen the quality of her analysis firsthand. She is an accomplished equity analyst in her own right with a unique combination of talents and is a timely addition to our research efforts. Most recently, Noelle has been on the frontline of the fight against COVID-19 in her capacity as an emergency medicine physician at a high-volume urban health center where she has treated countless patients infected with the virus. Dr. Tune will focus on covering public and private investments in the therapeutics and services areas.

 

As always, please don’t hesitate to reach out to us with any questions or comments.

  

Sincerely,

 

(GRAPHIC)  

 

Charles I Clough, Jr.

  

(GRAPHIC)  

 

Robert M. Zdunczyk

 

This letter is provided for informational purposes only and is not an offer to purchase or sell shares. Clough Opportunities Fund (the “Fund”) is a closed-end fund, which is traded on the NYSE American LLC, and does not continuously issue shares for sale as open-end mutual funds do. The market price of a closed-end fund is based on the market’s value.

 

Although not generally stated throughout, the information in this letter reflects the opinions of the individual portfolio managers, which opinion is subject to change, and is not intended to be a forecast of future events, a guarantee of future results or investment advice.

 

 

14 www.cloughglobal.com

 

 

Clough Global Opportunities Fund Shareholder Letter

 

October 31, 2020 (Unaudited)

 

The MSCI World Index is a free float-adjusted market capitalization weighted index that is designed to measure the equity market performance of 23 developed markets countries. Both indices referenced herein reflect the reinvestment of dividends. Effective July 31, 2010, the MSCI World Index returns prior to January 1, 2002 were revised to reflect the total returns, with dividends reinvested, reported by MSCI. The MSCI information may only be used for your internal use, may not be reproduced or redisseminated in any form and may not be used as a basis for or a component of any financial instruments or products or indices. None of the MSCI information is intended to constitute investment advice or a recommendation to make (or refrain from making) any kind of investment decision and may not be relied on as such. Historical data and analysis should not be taken as an indication or guarantee of any future performance analysis, forecast or prediction. The MSCI information is provided on an “as is” basis and the user of this information assumes the entire risk of any use made of this information. MSCI, each of its affiliates and each other person involved in or related to compiling, computing or creating any MSCI information (collectively, the “MSCI Parties”) expressly disclaims all warranties (including, without limitation, any warranties of originality, accuracy, completeness, timeliness, non-infringement, merchantability and fitness for a particular purpose) with respect to this information. Without limiting any of the foregoing, in no event shall any MSCI Party have any liability for any direct, indirect, special, incidental, punitive, consequential (including, without limitation, lost profits) or any other damages (www.msci.com).

 

The Bloomberg Barclays US Aggregate Bond Index measures the performance of the U.S. investment grade bond market. The Barclays Aggregate Bond index invests in a wide spectrum of public, investment-grade, taxable, fixed income securities in the United States, including government, corporate, and international dollar-denominated bonds, as well as mortgage-backed and asset-backed securities, all with maturities of more than 1 year.

 

The performance of the indices referenced herein is used for informational purposes only. One cannot invest directly in an index. Indices are not subject to any of the fees or expenses to which the Fund is subject, and there are significant differences between the Fund’s investments and the components of the indices referenced.

 

The net asset value (NAV) of a closed-end fund is the market price of the underlying investments (i.e., stocks and bonds) in the fund’s portfolio, minus liabilities, divided by the total number of fund shares outstanding. However, the fund also has a market price; the value of which it trades on an exchange. This market price can be more or less than its NAV.

 

RISKS 

An investor should consider investment objectives, risks, charges and expenses carefully before investing. To obtain an annual report or semiannual report which contains this and other information visit www.cloughglobal.com or call 1-877-256-8445. Read them carefully before investing.

 

A Fund’s distribution policy will, under certain circumstances, have certain adverse consequences to the Fund and its shareholders because it may result in a return of capital resulting in less of a shareholder’s assets being invested in the Fund and, over time, increase the Fund’s expense ratio.

 

Distributions may be paid from sources of income other than ordinary income, such as net realized short-term capital gains, net realized long-term capital gains and return of capital. Based on current estimates, we anticipate the most recent distribution has been paid from short-term and long-term capital gains. The actual amounts and sources of the amounts for tax reporting purposes will depend upon a Fund’s investment experience during the remainder of its fiscal year and may be subject to changes based on tax regulations. If a distribution includes anything other than net investment income, the Fund provides a Section 19(a) notice of the best estimate of its distribution sources at that time. These estimates may not match the final tax characterization (for the full year’s distributions) contained in shareholders’ 1099-DIV forms after the end of the year.

 

A Fund’s investments in securities of foreign issuers are subject to risks not usually associated with owning securities of U.S. issuers. These risks can include fluctuations in foreign currencies, foreign currency exchange controls, social, political and economic instability, differences in securities regulation and trading, expropriation or nationalization of assets, and foreign taxation issues.

 

A Fund’s investments in preferred stocks and bonds of below investment grade quality (commonly referred to as “high yield” or “junk bonds”), if any, are predominately speculative because of the credit risk of their issuers.

 

An investment by a Fund in REITs will subject it to various risks. The first, real estate industry risk, is the risk that the REIT share prices will decline because of adverse developments affecting the real estate industry and real property values. In general, real estate values can be affected by a variety of factors, including supply and demand for properties, the economic health of the country or of different regions, and the strength of specific industries that rent properties. The second, investment style risk, is the risk that returns from REITs—which typically are small or medium capitalization stocks—will trail returns from the overall stock market. The third, interest rate risk, is the risk that changes in interest rates may hurt real estate values or make REIT shares less attractive than other income-producing investments. Credit risk is the risk that an issuer of a preferred or debt security will become unable to meet its obligation to make dividend, interest and principal payments.

 

Interest rate risk is the risk that preferred stocks paying fixed dividend rates and fixed-rate debt securities will decline in value because of changes in market interest rates. When interest rates rise the value of such securities generally will fall. Derivative transactions (such as futures contracts and options thereon, options, swaps, and short sales) subject a Fund to increased risk of principal loss due to imperfect correlation or unexpected price or interest rate movements. Compared to investment companies that focus only on large companies, the Fund’s share price may be more volatile because it also invests in small and medium capitalization companies.

 

Past performance is neither a guarantee, nor necessarily indicative, of future results, which may be significantly affected by changes in economic and other conditions.

 

 

Annual Report | October 31, 2020 15

 

 

Clough Global Opportunities Fund Portfolio Allocation

 

October 31, 2020 (Unaudited)

 

Top 10 Equity Holdings(a)(d) % of Total Portfolio
1. PennyMac Financial Services, Inc. 4.67%
2. Taiwan Semiconductor Manufacturing Co., Ltd. 2.49%
3. Quest Diagnostics, Inc. 2.48%
4. First American Financial Corp. 2.40%
5. Apple, Inc. 2.37%
6. Annaly Capital Management, Inc. 2.34%
7. Hologic, Inc. 2.18%
8. AGNC Investment Corp. 2.03%
9. CRISPR Therapeutics AG 1.96%
10. Sany Heavy Industry Co., Ltd. 1.93%

 

Global Securities Holdings(a) % of Total Portfolio
United States 71.42%
U.S. Multinationals(b) 11.35%
China 10.38%
Taiwan 2.49%
Switzerland 1.83%
Hong Kong 1.28%
United Kingdom 1.15%
Canada 0.99%
Japan 0.58%
Other -1.47%
TOTAL INVESTMENTS 100.00%
Asset Allocation(a) % of Total Portfolio
Common Stock - US 51.68%
Common Stock - Foreign 22.32%
Total Return Swap Contracts 5.07%
Total Equities 79.07%
   
Government L/T 12.01%
Corporate Debt 2.32%
Municipal Bond 0.47%
Total Fixed Income 14.80%
   
Short-Term Investments 1.92%
Other (Cash) 1.67%
Futures 1.64%
Purchased Options 0.90%
   
TOTAL INVESTMENTS 100.00%

 

Country Allocation(c)

Long 

Exposure 

%TNA 

Short 

Exposure 

%TNA 

Gross 

Exposure 

%TNA 

Net 

Exposure 

%TNA 

United States 108.7% -2.4% 111.1% 106.3%
U.S. Multinationals(b) 21.8% -4.9% 26.7% 16.9%
China 15.5% 0.0% 15.5% 15.5%
Taiwan 3.7% 0.0% 3.7% 3.7%
Switzerland 3.3% -0.6% 3.9% 2.7%
Hong Kong 1.9% 0.0% 1.9% 1.9%
United Kingdom 1.7% 0.0% 1.7% 1.7%
Canada 1.5% 0.0% 1.5% 1.5%
Japan 0.9% 0.0% 0.9% 0.9%
Other 0.8% -3.0% 3.8% -2.2%
TOTAL INVESTMENTS 159.8% -10.9% 170.7% 148.9%

 

(a) Percentages calculated based on total portfolio, including securities sold short, cash balances, market value of futures, and notional value of return swaps.

(b) U.S. Multinationals includes companies organized or located in the United States that have more than 50% of revenues derived outside of the United States.

(c) Percentages calculated based on the net asset value of the Fund.

(d) Only long equity and equity-related positions are listed.


 

16 www.cloughglobal.com

 

 

Clough Global Dividend and Income Fund Statement of Investments

 

October 31, 2020

 

    Shares     Value  
COMMON STOCKS 90.01%                
Communication Services 1.49%                
Tencent Holdings, Ltd.     16,800     $ 1,280,722  
                 
Consumer Discretionary 7.67%                
DR Horton, Inc.(a)(b)     38,600       2,578,866  
Lennar Corp. - Class A(a)(b)     34,800       2,444,004  
Samsonite International S.A.(c)     708,900       713,244  
Xinyi Glass Holdings, Ltd.     392,000       858,582  
              6,594,696  
                 
Financials 32.23%                
AGNC Investment Corp.(a)     192,200       2,685,034  
Annaly Capital Management, Inc.(a)     446,600       3,166,394  
Ares Capital Corp.     30,200       417,666  
Bank of America Corp.(a)(b)     84,661       2,006,466  
Barings BDC, Inc.(a)     183,800       1,380,338  
Citigroup, Inc.(a)(b)     34,706       1,437,523  
First American Financial Corp.(a)(b)     72,300       3,223,857  
Golub Capital BDC, Inc.(a)     105,775       1,344,400  
Hong Kong Exchanges and Clearing, Ltd.     35,200       1,680,882  
JPMorgan Chase & Co.(a)(b)     13,200       1,294,128  
PennyMac Financial Services, Inc.(a)     133,000       6,759,060  
Sixth Street Specialty Lending, Inc.(a)(b)     94,400       1,553,824  
Stewart Information Services Corp.(a)     18,300       775,737  
              27,725,309  
                 
Health Care 19.68%                
AbbVie, Inc.(a)     12,700       1,080,770  
Amgen, Inc.(a)(b)     7,879       1,709,270  
Baxter International, Inc.(a)(b)     10,900       845,513  
Eli Lilly & Co.(a)(b)     9,213       1,201,928  
McKesson Corp.     9,050       1,334,785  
Quest Diagnostics, Inc.(a)(b)     46,305       5,655,693  
Thermo Fisher Scientific, Inc.(a)(b)     4,776       2,259,621  
Zimmer Biomet Holdings, Inc.(a)(b)     6,090       804,489  
Zoetis, Inc.(a)(b)     12,855       2,038,160  
              16,930,229  
                 
Information Technology 21.75%                
Apple, Inc.(a)(b)     49,515       5,390,203  
Infineon Technologies AG     23,959       666,900  
Intuit, Inc.(a)     2,505       788,273  
Lam Research Corp.(a)(b)     3,460       1,183,597  
Mastercard, Inc. - Class A(a)     2,269       654,924  
Microsoft Corp.(a)(b)     24,527       4,965,982  
Samsung Electronics Co., Ltd.     19,414       968,390  
Skyworks Solutions, Inc.(a)     5,690       803,940  
Taiwan Semiconductor Manufacturing Co., Ltd.     59,000       891,080  
    Shares     Value  
Information Technology (continued)
Taiwan Semiconductor Manufacturing Co., Ltd. - Sponsored ADR(a)(b)     28,600     $ 2,398,682  
              18,711,971  
                 
Real Estate 7.19%                
Community Healthcare Trust, Inc.(a)     115,000       5,324,500  
Physicians Realty Trust(a)     51,000       859,860  
              6,184,360  
                 
TOTAL COMMON STOCKS                
(Cost $66,654,029)             77,427,287  
                 
PREFERRED STOCKS 1.29%                
Gabelli Equity Trust, Inc.                
Series K, Perpetual Maturity 5.000%(d)     21,200       566,271  
Trinity Capital, Inc., 01/16/2025 7.000%(a)(b)(e)     22,400       543,760  
                 
TOTAL PREFERRED STOCKS                
(Cost $1,090,000)             1,110,031  
                 

Underlying Security/Expiration Date/Exercise Price/Notional Amount

  Contracts     Value  
PURCHASED OPTIONS 0.76%                
Call Options Purchased 0.76%                
CRISPR Therapeutics AG                
01/15/21, $90, $2,111,860     230       355,350  
Eurodollar Future Option                
12/14/21, $100, $359,457,450     1,441       99,069  
12/14/21, $99.875, $523,845,000     2,100       196,875  
                 
Total Call Options Purchased                
(Cost $1,347,000)             651,294  
             
Description/Maturity Date/Rate  

Principal

Amount

    Value  
CORPORATE BONDS 18.08%                
Agile Group Holdings, Ltd.                
11/23/2020, 9.500%(f)   $ 250,000       250,764  
Amazon.com, Inc.                
06/03/2050, 2.500%     1,000,000       989,912  
Amgen, Inc.                
02/21/2030, 2.450%(a)(b)     400,000       421,996  
Arrow Electronics, Inc.                
01/12/2028, 3.875%     300,000       333,543  
Brown University in Providence in the State of Rhode Island and Providence Plant                
Series A, 09/01/2050, 2.924%     500,000       528,527  


 

 
Annual Report | October 31, 2020 17

 

 

Clough Global Dividend and Income Fund Statement of Investments
 

October 31, 2020

 

Description/Maturity Date/Rate  

Principal

Amount

    Value  
CORPORATE BONDS (continued)
Carvana Co.                
10/01/2028, 5.875%(e)   $ 1,000,000     $ 988,960  
Centene Corp.                
01/15/2025, 4.750%     250,000       257,187  
01/15/2025, 4.750%(a)     160,000       164,600  
Citrix Systems, Inc.                
03/01/2030, 3.300%     800,000       841,782  
Commonwealth Edison Co.                
03/01/2045, 3.700%     500,000       573,741  
Duke University                
Series 2020, 10/01/2044, 2.682%     300,000       306,441  
Eli Lilly and Co.                
03/15/2029, 3.375%(a)(b)     400,000       461,388  
09/15/2060, 2.500%     500,000       467,060  
Fidelity National Financial, Inc.                
03/15/2031, 2.450%     850,000       832,833  
JPMorgan Chase & Co.                
10/15/2030, 1D US SOFR + 1.51%(g)     500,000       534,746  
Lennar Corp.                
01/15/2022, 4.125%     450,000       461,531  
Melco Resorts Finance, Ltd.                
07/21/2028, 5.750%(e)     250,000       249,442  
Microchip Technology, Inc.                
09/01/2023, 2.670%(e)     500,000       519,154  
Molson Coors Beverage Co.                
07/15/2026, 3.000%     300,000       322,655  
Nestle Holdings, Inc.                
09/24/2038, 3.900%(e)     200,000       248,802  
Prudential Financial, Inc.                
12/07/2049, 3.935%     500,000       566,765  
PulteGroup, Inc.                
03/01/2026, 5.500%(a)     300,000       347,062  
Regeneron Pharmaceuticals, Inc.                
09/15/2030, 1.750%     500,000       482,412  
09/15/2050, 2.800%     400,000       375,581  
Solar Capital, Ltd.                
01/20/2023, 4.500%     500,000       506,442  
Stanford Health Care                
Series 2020, 08/15/2030, 3.310%     300,000       336,129  
Sunac China Holdings, Ltd.                
04/19/2023, 8.350%(f)     750,000       770,095  
Times China Holdings, Ltd.                
06/04/2021, 7.850%(f)     500,000       505,287  
Toll Brothers Finance Corp.                
11/01/2029, 3.800%(a)     500,000       532,420  
University of Notre Dame du Lac                
Series 2020, 02/15/2030, 1.637%     300,000       301,728  
University of Southern California                
10/01/2039, 3.028%     630,000       671,138  
Description/Maturity Date/Rate    

Principal

Amount

      Value  
CORPORATE BONDS (continued)
Yale University                
Series 2020, 04/15/2030, 1.482%   $ 400,000     $ 401,487  
                 
TOTAL CORPORATE BONDS                
(Cost $15,656,123)             15,551,610  
                 
CONVERTIBLE CORPORATE BONDS 3.43%
Ares Capital Corp.                
02/01/2022, 3.750%(a)(b)     550,000       554,400  
Gossamer Bio, Inc.                
06/01/2027, 5.000%(a)(b)     1,070,000       877,082  
Starwood Property Trust, Inc.                
04/01/2023, 4.375%     400,000       386,789  
Teladoc Health, Inc.                
06/01/2027, 1.250%(a)(b)(e)     700,000       818,490  
Two Harbors Investment Corp.                
01/15/2022, 6.250%     314,000       313,804  
                 
TOTAL CONVERTIBLE CORPORATE BONDS
(Cost $3,026,528)             2,950,565  
                 
ASSET-BACKED SECURITIES 0.08%
United States Small Business Administration                
Series 2008-20L, Class 1, 12/01/2028, 6.220%(a)(b)     59,867       66,659  
                 
TOTAL ASSET-BACKED SECURITIES
(Cost $59,867)             66,659  
                 
GOVERNMENT & AGENCY OBLIGATIONS 32.14%
U.S. Treasury Bonds                
02/15/2050, 2.000%(a)     3,000,000       3,248,437  
05/15/2050, 1.250%     550,000       496,719  
08/15/2050, 1.375%(a)     7,500,000       6,992,578  
U.S. Treasury Notes                
01/31/2021, 2.500%     1,000,000       1,005,743  
02/28/2025, 1.125%(a)     5,900,000       6,105,578  
03/31/2025, 2.625%     2,700,000       2,971,266  
02/28/2027, 1.125%(a)     6,600,000       6,828,293  
                 
TOTAL GOVERNMENT & AGENCY OBLIGATIONS
(Cost $28,372,743)             27,648,614  
                 
MUNICIPAL BONDS 0.89%                
Massachusetts State College Building Authority, Higher Education Revenue Bonds                
05/01/2040, 2.972%     300,000       293,694  


 

 
18 www.cloughglobal.com

 

 

Clough Global Dividend and Income Fund Statement of Investments

 

October 31, 2020

 

Description/Maturity Date/Rate  

Principal

Amount

    Value  
MUNICIPAL BONDS (continued)                
University of Virginia, Higher Education Revenue Bonds                
09/01/2050, 2.256%   $ 500,000     $ 470,610  
                 
TOTAL MUNICIPAL BONDS                
(Cost $814,451)             764,304  
                 
    Shares     Value  
SHORT-TERM INVESTMENTS 4.77%
Money Market Funds 4.77%                
BlackRock Liquidity Funds, T-Fund Portfolio - Institutional Class (0.040% 7-day yield)     4,104,432       4,104,432  
                 
TOTAL SHORT-TERM INVESTMENTS
(Cost $4,104,432)             4,104,432  
                 
Total Investments - 151.45%                
(Cost $121,125,173)             130,274,796  
                 
Liabilities in Excess of Other Assets - (51.45%)(h)       (44,258,738 )
                 
NET ASSETS - 100.00%           $ 86,016,058  
                 

SCHEDULE OF SECURITIES

SOLD SHORT(c)

  Shares     Value  
COMMON STOCKS (11.39%)                
Consumer Discretionary (0.64%)                
Vroom, Inc.     (13,400 )     (550,740 )
                 
Financials (3.48%)                
Deutsche Bank AG     (203,600 )     (1,883,300 )
Invesco, Ltd.     (28,500 )     (373,635 )
Mediobanca Banca di Credito Finanziario SpA     (40,686 )     (288,479 )
Societe Generale S.A.     (8,443 )     (114,457 )
UniCredit SpA     (44,837 )     (334,255 )
              (2,994,126 )
                 
Health Care (1.65%)                
Bruker Corp.     (14,100 )     (599,814 )
PRA Health Sciences, Inc.     (8,415 )     (819,958 )
              (1,419,772 )
                 
Information Technology (5.62%)                
Cree, Inc.     (18,600 )     (1,182,960 )
International Business Machines Corp.     (23,535 )     (2,627,918 )
Qualys, Inc.     (5,500 )     (483,175 )

SCHEDULE OF SECURITIES

SOLD SHORT(c) (continued)

  Shares     Value  
Information Technology (continued)
Temenos AG     (4,980 )   $ (534,632 )
              (4,828,685 )
                 
TOTAL COMMON STOCKS
(Proceeds $9,830,902)             (9,793,323 )
                 
TOTAL SECURITIES SOLD SHORT                
(Proceeds $9,830,902)           $ (9,793,323 )

 

 
Annual Report | October 31, 2020 19

 

 

Clough Global Dividend and Income Fund Statement of Investments

 

October 31, 2020

 

Investment Abbreviations:

1D FEDEF - Federal Funds Effective Rate (Daily)

SOFR - Secured Overnight Financing Rate

 

FEDEF Rates:

1D FEDEF - 1 Day FEDEF as of October 31, 2020 was 0.09%

 

SOFR Rates:

1D SOFR as of October 31, 2020 was 0.09%

 

(a)  Pledged security; a portion or all of the security is pledged as collateral for securities sold short, total return swap contracts, or borrowings. As of October 31, 2020, the aggregate value of those securities was $89,389,815, representing 103.92% of net assets. (See Note 1)
(b)  Loaned security; a portion or all of the security is on loan as of October 31, 2020.
(c)  Non-income producing security.
(d)  This security has no contractual maturity date, is not redeemable and contractually pays an indefinite stream of interest.
(e)  Security is exempt from registration of the Securities Act of 1933. These securities may be resold in transactions exempt from registration under Rule 144A, normally to qualified institutional buyers. As of October 31, 2020, these securities had an aggregate value of $3,368,608 or 3.92% of net assets.
(f)  Securities were purchased pursuant to Regulation S under the Securities Act of 1933, which exempts securities offered and sold outside of the United States from registration. Such securities cannot be sold in the United States without either an effective registration statement filed pursuant to the Securities Act of 1933, or pursuant to an exemption from registration. These securities have been deemed liquid under guidelines approved by the Fund's Board of Trustees. As of October 31, 2020, the aggregate value of those securities was $1,526,146, representing 1.77% of net assets.
(g)  Variable rate investment. Interest rates reset periodically. Interest rate shown reflects the rate in effect at October 31, 2020. For securities based on a published reference rate and spread, the reference rate and spread are indicated in the description above.
(h)  Includes cash which is being held as collateral for futures contracts, total return swap contracts and securities sold short.

 

For Fund compliance purposes, the Fund’s sector classifications refer to any one of the sector sub-classifications used by one or more widely recognized market indexes, and/or as defined by Fund management. This definition may not apply for purposes of this report, which may combine sector sub-classifications for reporting ease. Sectors are shown as a percent of net assets. These sector classifications are unaudited.


 

 
20 www.cloughglobal.com

 

 

Clough Global Dividend and Income Fund Statement of Investments

 

October 31, 2020

 

FUTURES CONTRACTS

Description   Counterparty   Position   Contracts  

Expiration

Date

 

Notional

Value

   

Unrealized

Appreciation/

(Depreciation)

 
EURODOLLAR 90 DAY   Morgan Stanley   Long   1,447   June 2021   $ 361,026,500     $ 2,453,752  
EURODOLLAR 90 DAY   Morgan Stanley   Long   369   March 2022     91,996,312       (116,920 )
                    $ 453,022,812     $ 2,336,832  

 

TOTAL RETURN SWAP CONTRACTS

Counter Party  

Reference

Entity/Obligation

 

Notional

Amount

   

Floating Rate

Paid by

the Fund

 

Floating

Rate Index

 

Termination

Date

  Value    

Net

Unrealized

Appreciation

 
Morgan Stanley   Banco Santander SA   $ (89,724 )   1D FEDEF - 50 bps   1D FEDEF   05/20/2022   $ (85,093 )   $ 4,631  
Morgan Stanley   Kweichow Moutai Co., Ltd.     588,373     1D FEDEF - 250 bps   1D FEDEF   01/06/2022     770,180       181,807  
Morgan Stanley   Sany Heavy Industry Co., Ltd.     2,161,971     1D FEDEF - 250 bps   1D FEDEF   01/06/2022     2,955,501       793,530  
Morgan Stanley   Wuliangye Yibin Co., Ltd.     423,129     1D FEDEF - 255 bps   1D FEDEF   05/04/2022     795,026       371,897  
        $ 3,083,749                 $ 4,435,614     $ 1,351,865  

 

Counter Party  

Reference

Entity/Obligation

   

Notional

Amount

   

Floating Rate

Paid by

the Fund

 

Floating

Rate Index

 

Termination

Date

    Value      

Net

Unrealized

Depreciation

 
Morgan Stanley   Luxshare Precision Industry Co., Ltd.   $ 746,462     1D FEDEF - 250 bps   1D FEDEF   01/06/2022   $ 741,815     $ (4,647 )
        $ 746,462                 $ 741,815     $ (4,647 )

 

See Notes to the Financial Statements.

 

 
Annual Report | October 31, 2020 21

 

 

Clough Global Equity Fund Statement of Investments

 

October 31, 2020

 

    Shares     Value  
COMMON STOCKS 128.67%                
Communication Services 6.41%                
Alphabet, Inc. - Class C(a)(b)     2,755     $ 4,465,882  
Facebook, Inc. - Class A(a)(b)(c)     15,105       3,974,277  
Tencent Holdings, Ltd.     31,750       2,420,413  
              10,860,572  
                 
Consumer Discretionary 18.00%                
Alibaba Group Holding, Ltd.(a)     85,050       3,216,596  
Amazon.com, Inc.(a)(b)(c)     1,626       4,936,780  
Carnival Corp.(b)(c)     152,500       2,090,775  
Carvana Co.(a)(b)     18,950       3,512,383  
DR Horton, Inc.(b)(c)     70,900       4,736,829  
Lennar Corp. - Class A(b)(c)     63,700       4,473,651  
Meituan - Class B(a)     62,300       2,316,009  
Royal Caribbean Cruises Ltd.(b)(c)     68,720       3,877,182  
Samsonite International S.A.(a)     1,356,000       1,364,308  
              30,524,513  
                 
Financials 30.16%                
AGNC Investment Corp.(b)     420,100       5,868,797  
Annaly Capital Management, Inc.(b)     832,800       5,904,552  
Ares Capital Corp.(b)     57,400       793,842  
Bank of America Corp.(b)(c)     178,095       4,220,852  
Barings BDC, Inc.     120,846       907,554  
Citigroup, Inc.(b)(c)     65,962       2,732,146  
First American Financial Corp.(b)(c)     149,700       6,675,123  
Golub Capital BDC, Inc.(b)     152,461       1,937,779  
Hong Kong Exchanges and Clearing, Ltd.     66,900       3,194,631  
JPMorgan Chase & Co.(b)(c)     28,250       2,769,630  
PennyMac Financial Services, Inc.(b)     233,400       11,861,387  
Sixth Street Specialty Lending, Inc.(b)(c)     170,000       2,798,200  
Stewart Information Services Corp.(b)     34,600       1,466,694  
              51,131,187  
                 
Health Care 46.89%                
1Life Healthcare, Inc.(a)(b)(c)     119,600       3,373,916  
AbbVie, Inc.(b)     24,000       2,042,400  
Amgen, Inc.(b)(c)     14,754       3,200,733  
Amphivena Therapeutics, Inc. - Series C(a)(d)(e)(f)(g)     334,425       1,308,431  
Apellis Pharmaceuticals, Inc.(a)(b)(c)     77,397       2,468,964  
Arcellx, Inc.(a)(d)(e)(f)(g)     234,345       420,485  
Baxter International, Inc.(b)(c)     21,000       1,628,970  
Centrexion Therapeutics Corp.(a)(e)(f)(g)     4,336       51,741  
Centrexion Therapeutics Corp.(a)(d)(e)(f)(g)     66,719       796,158  
Checkmate Pharmaceuticals, Inc.(a)(b)(c)     157,641       1,811,295  
    Shares     Value  
Health Care (continued)                
Checkmate Pharmaceuticals, Inc.(a)(d)(e)(g)     112,731     $ 1,261,098  
Covetrus, Inc.(a)(b)     114,100       2,817,129  
CRISPR Therapeutics AG(a)(b)     46,080       4,231,066  
Flexion Therapeutics, Inc.(a)(b)(c)     266,500       3,195,335  
Fusion Pharmaceuticals, Inc.(a)     78,000       967,200  
Gossamer Bio, Inc.(a)(b)     87,821       728,914  
GW Pharmaceuticals PLC - ADR(a)(b)(c)     31,958       2,876,540  
Hologic, Inc.(a)(b)(c)     80,000       5,505,600  
Idorsia, Ltd.(a)     21,806       571,696  
Laboratory Corp. of America Holdings(a)(b)(c)     18,410       3,677,766  
McKesson Corp.(b)     17,100       2,522,079  
Mirati Therapeutics, Inc.(a)(b)     6,570       1,426,610  
Moderna, Inc.(a)(b)(c)     58,322       3,934,985  
Quest Diagnostics, Inc.(b)(c)     50,940       6,221,812  
Regeneron Pharmaceuticals, Inc.(a)(b)(c)     3,920       2,130,755  
Repare Therapeutics, Inc.(a)(b)     56,200       1,519,086  
SmileDirectClub, Inc.(a)(b)     158,400       1,409,760  
Teladoc Health, Inc.(a)(b)(c)     14,529       2,854,367  
Thermo Fisher Scientific, Inc.(b)     8,934       4,226,854  
Veracyte, Inc.(a)(b)     74,710       2,589,449  
Vertex Pharmaceuticals, Inc.(a)(b)(c)     16,045       3,343,136  
Vir Biotechnology, Inc.(a)(b)     12,790       402,118  
Zai Lab, Ltd. - ADR(a)(b)(c)     35,290       2,895,544  
Zoetis, Inc.(b)(c)     6,855       1,086,860  
              79,498,852  
                 
Information Technology 24.60%                
Advanced Energy Industries, Inc.(a)(b)     29,400       1,983,618  
Apple, Inc.(b)(c)     55,040       5,991,654  
Crowdstrike Holdings, Inc. - Class A(a)(b)     11,040       1,367,194  
Five9, Inc.(a)(b)     11,670       1,770,572  
Infineon Technologies AG     46,376       1,290,878  
Intuit, Inc.(b)     4,650       1,463,262  
Lam Research Corp.(b)(c)     6,155       2,105,502  
Lumentum Holdings, Inc.(a)(b)     19,400       1,604,186  
Mastercard, Inc. - Class A(b)     4,390       1,267,130  
Microsoft Corp.(b)     22,229       4,500,706  
Qorvo, Inc.(a)     17,540       2,233,894  
Renesas Electronics Corp.(a)     178,800       1,470,431  
RingCentral, Inc. - Class A(a)(b)     5,105       1,318,826  
salesforce.com, Inc.(a)(b)(c)     4,089       949,752  
Skyworks Solutions, Inc.(b)     10,830       1,530,171  
Splunk, Inc.(a)(b)     7,010       1,388,260  
Taiwan Semiconductor Manufacturing Co., Ltd. - Sponsored ADR(b)(c)     54,500       4,570,915  
Taiwan Semiconductor Manufacturing Co., Ltd.     111,000       1,676,438  
Twilio, Inc. - Class A(a)(b)     5,600       1,562,232  


 

22 www.cloughglobal.com

 

 

Clough Global Equity Fund Statement of Investments

 

October 31, 2020

 

    Shares     Value  
Information Technology (continued)                
Workday, Inc. - Class A(a)(b)(c)     7,905     $ 1,660,999  
              41,706,620  
                 
Real Estate 2.61%                
Community Healthcare Trust, Inc.(b)     64,650       2,993,295  
Physicians Realty Trust(b)     84,600       1,426,356  
              4,419,651  
                 
TOTAL COMMON STOCKS                
(Cost $198,770,629)             218,141,395  

 

Underlying Security/Expiration Date/ 

Exercise Price/Notional Amount 

  Contracts     Value  
PURCHASED OPTIONS 1.33%                
Call Options Purchased 1.33%                
CRISPR Therapeutics AG                
01/15/21, $90, $4,131,900     450       695,250  
Eurodollar Future Option                
12/14/21, $100, $654,307,350     2,623       180,332  
12/14/21, $99.875, $997,800,000     4,000       375,000  
Hologic, Inc.                
12/18/20, $70, $8,086,350     1,175       511,125  
Vertex Pharmaceuticals, Inc.                
01/15/21, $210, $7,084,240     340       498,100  
                 
Total Call Options Purchased                
(Cost $3,415,259)             2,259,807  

 

Description/Maturity Date/Rate  

Principal 

Amount 

    Value  
GOVERNMENT & AGENCY OBLIGATIONS 15.15%
U.S. Treasury Bonds                
02/15/2050, 2.000%(b)   $ 6,800,000       7,363,125  
05/15/2050, 1.250%     2,700,000       2,438,437  
08/15/2050, 1.375%     8,000,000       7,458,750  
U.S. Treasury Notes                
02/28/2027, 1.125%     2,000,000       2,069,180  
02/15/2030, 1.500%(b)     6,000,000       6,360,000  
                 
TOTAL GOVERNMENT & AGENCY OBLIGATIONS
(Cost $26,843,161)             25,689,492  

 

    Shares     Value  
SHORT-TERM INVESTMENTS 1.95%                
Money Market Funds 1.95%                
BlackRock Liquidity Funds, T-Fund Portfolio - Institutional Class (0.040% 7-day yield)     3,307,238       3,307,238  
                 
TOTAL SHORT-TERM INVESTMENTS
(Cost $3,307,238)             3,307,238  
    Value  
Total Investments - 147.10%        
(Cost $232,336,287)   $ 249,397,932  
         
Liabilities in Excess of Other Assets - (47.10%)(h)     (79,856,007 )
         
NET ASSETS - 100.00%   $ 169,541,925  

 

SCHEDULE OF SECURITIES

SOLD SHORT(a) 

  Shares     Value  
COMMON STOCKS (10.60%)                
Consumer Discretionary (0.64%)                
Vroom, Inc.     (26,200 )     (1,076,820 )
                 
Financials (3.14%)                
Deutsche Bank AG     (356,200 )     (3,294,850 )
Invesco, Ltd.     (55,300 )     (724,983 )
Mediobanca Banca di Credito Finanziario SpA     (67,513 )     (478,692 )
Societe Generale S.A.     (14,196 )     (192,448 )
UniCredit SpA     (84,636 )     (630,953 )
              (5,321,926 )
                 
Health Care (1.47%)                
Bruker Corp.     (24,420 )     (1,038,827 )
PRA Health Sciences, Inc.     (14,885 )     (1,450,394 )
              (2,489,221 )
                 
Information Technology (5.35%)                
Cree, Inc.     (34,900 )     (2,219,640 )
International Business Machines Corp.     (44,055 )     (4,919,181 )
Qualys, Inc.     (10,370 )     (911,005 )
Temenos AG     (9,531 )     (1,023,209 )
              (9,073,035 )
                 
TOTAL COMMON STOCKS                
(Proceeds $18,043,887)             (17,961,002 )
                 
TOTAL SECURITIES SOLD SHORT                
(Proceeds $18,043,887)           $ (17,961,002 )

 

Investment Abbreviations:  

1D FEDEF - Federal Funds Effective Rate (Daily)

 

FEDEF Rates:  

1D FEDEF - 1 Day FEDEF as of October 31, 2020 was 0.09%



 

Annual Report | October 31, 2020 23

 

 

Clough Global Equity Fund Statement of Investments

 

October 31, 2020

 

(a) Non-income producing security.
(b) Pledged security; a portion or all of the security is pledged as collateral for securities sold short, total return swap contracts, or borrowings. As of October 31, 2020, the aggregate value of those securities was $186,535,925, representing 110.02% of net assets. (See Note 1)
(c) Loaned security; a portion or all of the security is on loan as of October 31, 2020.
(d) All or a portion of the security is exempt from registration of the Securities Act of 1933. These securities may be resold in transactions exempt from registration under Rule 144A, normally to qualified institutional buyers. As of October 31, 2020, these securities had an aggregate value of $3,786,172 or 2.23% of net assets.
(e) Private Placement; these securities may only be resold in transactions exempt from registration under the Securities Act of 1933. As of October 31, 2020, these securities had an aggregate value of $3,837,913 or 2.26% of net assets.
(f) As a result of the use of significant unobservable inputs to determine fair value, these investments have been classified as Level 3 assets. (See Note 1)
(g) Fair valued security; valued by management in accordance with procedures approved by the Board. As of October 31, 2020, these securities had an aggregate value of $3,837,913 or 2.26% of total net assets.
(h) Includes cash which is being held as collateral for futures contracts, total return swap contracts and securities sold short.

 

For Fund compliance purposes, the Fund’s sector classifications refer to any one of the sector sub-classifications used by one or more widely recognized market indexes, and/or as defined by Fund management. This definition may not apply for purposes of this report, which may combine sector sub-classifications for reporting ease. Sectors are shown as a percent of net assets. These sector classifications are unaudited.



 

24 www.cloughglobal.com

 

 

Clough Global Equity Fund Statement of Investments

 

October 31, 2020

 

FUTURES CONTRACTS

 

Description

  Counterparty   Position   Contracts  

Expiration 

Date 

 

Notional 

Value 

   

Unrealized 

Appreciation/ 

(Depreciation) 

 
EURODOLLAR 90 DAY   Morgan Stanley   Long   2,467   June 2021   $ 615,516,500     $ 4,341,400  
EURODOLLAR 90 DAY   Morgan Stanley   Long   695   March 2022     173,272,188       (220,214 )
                    $ 788,788,688     $ 4,121,186  

 

TOTAL RETURN SWAP CONTRACTS

 

Counter Party  

Reference 

Entity/Obligation 

 

Notional 

Amount 

 

Floating Rate 

Paid by the Fund 

 

Floating 

Rate Index 

 

Termination 

Date 

  Value    

Net Unrealized 

Appreciation 

 
Morgan Stanley   Banco Santander SA   $ (153,443 ) 1D FEDEF -50 bps   1D FEDEF   05/20/2022   $ (145,523 )   $ 7,920  
Morgan Stanley   Kweichow Moutai Co., Ltd.     1,155,801   1D FEDEF -250 bps   1D FEDEF   01/06/2022     1,512,943       357,142  
Morgan Stanley   Luxshare Precision Industry Co., Ltd.     2,126,874   1D FEDEF - 250 bps   1D FEDEF   01/06/2022     2,591,584       464,710  
Morgan Stanley   Sany Heavy Industry Co., Ltd.     3,476,687   1D FEDEF -250 bps   1D FEDEF   01/06/2022     4,811,838       1,335,151  
Morgan Stanley   Wuliangye Yibin Co., Ltd.     830,731   1D FEDEF -255 bps   1D FEDEF   05/04/2022     1,560,876       730,145  
Morgan Stanley   Zoomlion Heavy Industry Science     2,204,767   1D FEDEF - 250 bps   1D FEDEF   01/06/2022     2,376,765       171,998  
TOTAL       $ 9,641,417               $ 12,708,483     $ 3,067,066  

 

See Notes to the Financial Statements. 

 

 

Annual Report | October 31, 2020 25

 

 

Clough Global Opportunities Fund Statement of Investments

 

October 31, 2020

 

    Shares     Value  
COMMON STOCKS 120.87%                
Communication Services 6.42%                
Alphabet, Inc. - Class C(a)(b)     5,469     $ 8,865,304  
Facebook, Inc. - Class A(a)(b)(c)     30,335       7,981,442  
Tencent Holdings, Ltd.     63,500       4,840,825  
              21,687,571  
                 
Consumer Discretionary 16.05%                
Alibaba Group Holding, Ltd.(a)     171,620       6,490,678  
Amazon.com, Inc.(a)(b)     1,670       5,070,371  
Carnival Corp.(b)(c)     303,840       4,165,646  
Carvana Co.(a)(b)     38,208       7,081,853  
DR Horton, Inc.(b)(c)     125,800       8,404,698  
Lennar Corp. - Class A(b)(c)     112,200       7,879,806  
Meituan - Class B(a)     123,400       4,587,408  
Royal Caribbean Cruises Ltd.(b)(c)     138,347       7,805,538  
Samsonite International S.A.(a)     2,718,600       2,735,257  
              54,221,255  
                 
Financials 27.72%                
AGNC Investment Corp.(b)     729,100       10,185,527  
Annaly Capital Management, Inc.(b)     1,660,100       11,770,109  
Ares Capital Corp.(b)     114,583       1,584,683  
Bank of America Corp.(b)     319,430       7,570,491  
Barings BDC, Inc.(b)     244,400       1,835,444  
Citigroup, Inc.(b)(c)     131,141       5,431,860  
First American Financial Corp.(b)(c)     270,565       12,064,493  
Golub Capital BDC, Inc.(b)     171,896       2,184,798  
Hong Kong Exchanges and Clearing, Ltd.     134,300       6,413,139  
JPMorgan Chase & Co.(b)(c)     49,800       4,882,392  
PennyMac Financial Services, Inc.(b)     462,080       23,482,905  
Sixth Street Specialty Lending, Inc.(b)(c)     198,627       3,269,400  
Stewart Information Services Corp.(b)(c)     69,400       2,941,866  
              93,617,107  
                 
Health Care 45.90%                
1Life Healthcare, Inc.(a)(b)(c)     239,600       6,759,116  
AbbVie, Inc.(b)     47,800       4,067,780  
Amgen, Inc.(b)(c)     29,570       6,414,916  
Amphivena Therapeutics, Inc. - Series C(a)(d)(e)(f)(g)     780,326       3,053,009  
Apellis Pharmaceuticals, Inc.(a)(b)(c)     156,301       4,986,002  
Arcellx, Inc.(a)(d)(e)(f)(g)     538,792       966,754  
Baxter International, Inc.(b)     42,100       3,265,697  
Centrexion Therapeutics Corp.(a)(e)(f)(g)     14,166       169,043  
Centrexion Therapeutics Corp.(a)(d)(e)(f)(g)     217,952       2,600,821  
    Shares     Value  
Health Care (continued)                
Checkmate Pharmaceuticals, Inc.(a)(d)(e)(g)     225,463     $ 2,522,208  
Checkmate Pharmaceuticals, Inc.(a)(b)(c)     320,465       3,682,143  
Covetrus, Inc.(a)(b)     226,800       5,599,692  
CRISPR Therapeutics AG(a)(b)     107,438       9,864,957  
Flexion Therapeutics, Inc.(a)(b)(c)     528,450       6,336,115  
Fusion Pharmaceuticals, Inc.(a)     156,700       1,943,080  
Gossamer Bio, Inc.(a)(b)     180,188       1,495,560  
GW Pharmaceuticals PLC - ADR(a)(b)(c)     64,064       5,766,401  
Hologic, Inc.(a)(b)(c)     159,300       10,963,026  
Laboratory Corp. of America Holdings(a)(b)(c)     36,895       7,370,514  
McKesson Corp.(b)(c)     34,020       5,017,610  
Mirati Therapeutics, Inc.(a)(b)     13,185       2,862,991  
Moderna, Inc.(a)(b)(c)     116,110       7,833,942  
Quest Diagnostics, Inc.(b)(c)     102,090       12,469,273  
Regeneron Pharmaceuticals, Inc.(a)(b)(c)     7,878       4,282,166  
Repare Therapeutics, Inc.(a)     111,679       3,018,683  
SmileDirectClub, Inc.(a)(b)     317,100       2,822,190  
Teladoc Health, Inc.(a)(b)(c)     29,541       5,803,625  
Thermo Fisher Scientific, Inc.(b)(c)     17,907       8,472,160  
Vertex Pharmaceuticals, Inc.(a)(b)(c)     32,153       6,699,399  
Vir Biotechnology, Inc.(a)     25,583       804,329  
Zai Lab, Ltd. - ADR(a)(b)(c)     71,220       5,843,601  
Zoetis, Inc.(b)(c)     8,005       1,269,193  
              155,025,996  
                 
Information Technology 22.36%                
Advanced Energy Industries, Inc.(a)     58,800       3,967,236  
Apple, Inc.(b)     109,610       11,932,145  
Crowdstrike Holdings, Inc. - Class A(a)(b)(c)     21,960       2,719,526  
Five9, Inc.(a)(b)(c)     23,350       3,542,662  
Infineon Technologies AG     92,045       2,562,076  
Intuit, Inc.(b)(c)     9,310       2,929,671  
Lam Research Corp.(b)(c)     7,660       2,620,333  
Lumentum Holdings, Inc.(a)     38,600       3,191,834  
Mastercard, Inc. - Class A(b)     8,717       2,516,075  
Microsoft Corp.(b)(c)     39,503       7,998,172  
Qorvo, Inc.(a)(b)(c)     35,270       4,491,987  
Renesas Electronics Corp.(a)     354,400       2,914,546  
RingCentral, Inc. - Class A(a)(b)(c)     10,220       2,640,235  
Skyworks Solutions, Inc.     21,610       3,053,277  
Splunk, Inc.(a)     14,060       2,784,442  
Taiwan Semiconductor Manufacturing Co., Ltd. - Sponsored ADR(b)(c)     108,800       9,125,056  
Taiwan Semiconductor Manufacturing Co., Ltd.     225,000       3,398,186  

 

 
26 www.cloughglobal.com

 

 

Clough Global Opportunities Fund Statement of Investments

 

October 31, 2020

 

    Shares     Value  
Information Technology (continued)
Twilio, Inc. - Class A(a)(b)(c)     11,200     $ 3,124,464  
              75,511,923  
                 
Real Estate 2.42%                
Community Healthcare Trust, Inc.(b)     113,356       5,248,383  
Physicians Realty Trust(b)     174,000       2,933,640  
              8,182,023  
                 
TOTAL COMMON STOCKS                
(Cost $373,011,039)             408,245,875  
                 
Underlying Security/Expiration Date/Exercise Price/Notional Amount   Contracts     Value  
PURCHASED OPTIONS 1.33%                
Call Options Purchased 1.33%                
CRISPR Therapeutics AG                
01/15/21, $90, $8,263,800     900       1,390,500  
Eurodollar Future Option                
12/14/21, $100, $1,322,833,350     5,303       364,581  
12/14/21, $99.875, $1,970,655,000     7,900       740,625  
Hologic, Inc.                
12/18/20, $70, $16,172,700     2,350       1,022,250  
Vertex Pharmaceuticals, Inc.                
01/15/21, $210, $13,960,120     670       981,550  
                 
Total Call Options Purchased                
(Cost $6,799,089)             4,499,506  
                 
Description/Maturity Date/Rate  

Principal

Amount

    Value  
CORPORATE BONDS 3.30%                
Agile Group Holdings, Ltd.                
11/23/2020, 9.500%(h)   $ 750,000       752,293  
Duke University                
Series 2020, 10/01/2044, 2.682%     1,500,000       1,532,203  
Fidelity National Financial, Inc.                
03/15/2031, 2.450%     1,400,000       1,371,725  
Regeneron Pharmaceuticals, Inc.                
09/15/2050, 2.800%     1,300,000       1,220,638  
Stanford Health Care                
Series 2020, 08/15/2030, 3.310%     1,300,000       1,456,558  
Sunac China Holdings, Ltd.                
04/19/2023, 8.350%(h)     2,250,000       2,310,284  
Times China Holdings, Ltd.                
06/04/2021, 7.850%(h)     1,500,000       1,515,860  
University of Notre Dame du Lac                
Series 2020, 02/15/2030, 1.637%     1,000,000       1,005,760  
                 
TOTAL CORPORATE BONDS                
(Cost $11,389,332)             11,165,321  
Description/Maturity Date/Rate  

Principal

Amount

    Value  
CONVERTIBLE CORPORATE BONDS 0.15%
Two Harbors Investment Corp.                
01/15/2022, 6.250%   $ 500,000     $ 499,688  
                 
TOTAL CONVERTIBLE CORPORATE BONDS
(Cost $498,986)             499,688  
                 
GOVERNMENT & AGENCY OBLIGATIONS 17.88%
U.S. Treasury Bonds                
11/15/2042, 2.750%(b)     8,420,000       10,434,551  
02/15/2050, 2.000%(b)     8,500,000       9,203,906  
05/15/2050, 1.250%     3,100,000       2,799,687  
08/15/2050, 1.375%     12,000,000       11,188,125  
U.S. Treasury Notes                
02/28/2025, 1.125%(b)     9,000,000       9,313,594  
03/31/2025, 2.625%     5,000,000       5,502,344  
02/28/2027, 1.125%(b)     5,400,000       5,586,785  
02/15/2030, 1.500%(b)     6,000,000       6,360,000  
                 
TOTAL GOVERNMENT & AGENCY OBLIGATIONS
(Cost $62,439,186)             60,388,992  
                 
MUNICIPAL BONDS 0.70%                
University of Virginia, Higher Education Revenue Bonds                
09/01/2050, 2.256%     2,500,000       2,353,050  
                 
TOTAL MUNICIPAL BONDS                
(Cost $2,531,041)             2,353,050  
                 
    Shares     Value  
SHORT-TERM INVESTMENTS 2.86%
Money Market Funds 2.86%                
BlackRock Liquidity Funds, T-Fund Portfolio - Institutional Class (0.040% 7-day yield)     9,658,221       9,658,221  
                 
TOTAL SHORT-TERM INVESTMENTS
(Cost $9,658,221)             9,658,221  
                 
Total Investments - 147.09%                
(Cost $466,326,894)             496,810,653  
                 
Liabilities in Excess of Other Assets - (47.09%)(i)       (159,049,392 )
                 
NET ASSETS - 100.00%           $ 337,761,261  
                 

SCHEDULE OF SECURITIES

SOLD SHORT(a)

  Shares     Value  
COMMON STOCKS (10.75%)                
Consumer Discretionary (0.63%)                
Vroom, Inc.     (51,800 )     (2,128,980 )


 

 
Annual Report | October 31, 2020 27

 

 

Clough Global Opportunities Fund Statement of Investments

 

October 31, 2020

 

SCHEDULE OF SECURITIES

SOLD SHORT(a) (continued)

  Shares     Value  
Financials (3.29%)            
Deutsche Bank AG     (721,443 )   $ (6,673,348 )
Invesco, Ltd.     (109,600 )     (1,436,856 )
Mediobanca Banca di Credito Finanziario SpA     (157,505 )     (1,116,768 )
Societe Generale S.A.     (30,516 )     (413,689 )
UniCredit SpA     (197,432 )     (1,471,836 )
              (11,112,497 )
                 
Health Care (1.49%)                
Bruker Corp.     (49,310 )     (2,097,647 )
PRA Health Sciences, Inc.     (30,090 )     (2,931,970 )
              (5,029,617 )
                 
Information Technology (5.34%)                
Cree, Inc.     (70,000 )     (4,452,000 )
International Business Machines Corp.     (88,130 )     (9,840,596 )
Qualys, Inc.     (19,490 )     (1,712,196 )
Temenos AG     (18,970 )     (2,036,542 )
              (18,041,334 )
                 
TOTAL COMMON STOCKS
(Proceeds $36,621,749)